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ABSTRACT 
 
Mismatches in DNA occur naturally during replication and as a result of endogenous 
DNA damaging agents, but the mismatch repair (MMR) pathway acts to correct 
mismatches before subsequent rounds of replication.  The loss of MMR carries dire 
consequences, including increased mutation rates, carcinogenesis, and resistance to a 
variety of clinical anti-cancer agents, such as cisplatin and DNA alkylators. Rhodium 
metalloinsertors previously developed in our laboratory bind to DNA mismatches with 
high affinity and specificity, and represent a promising strategy to target mismatches in 
cells.  Thus, uncorrected mismatches can be exploited to provide a basis of discrimination 
between MMR-deficient, cancerous cells and MMR-proficient, healthy cells. 
Here we describe the application of rhodium metalloinsertors to inhibit cellular 
proliferation selectively in MMR-deficient cells compared to those that are MMR-
proficient.  The colorectal carcinoma cell lines HCT116N and HCT116O serve as an 
isogenic model system for MMR deficiency. We show that the Δ-isomer of an octahedral 
rhodium complex containing a bulky chelate ligand for insertion into a DNA mismatch is 
active both in targeting base mismatches in vitro and in inhibiting DNA synthesis 
selectively in the HCT116O cell line. 
A family of derivative complexes with varying ancillary ligands has also been 
synthesized, and both DNA mismatch binding affinities and anti-proliferative activities 
against the HCT116 cell lines have been determined.  DNA photocleavage experiments 
reveal that all complexes bind to the mismatched sites with high specificities; DNA 
binding affinities to oligonucleotides containing single base CA and CC mismatches, 
 vii 
obtained through photocleavage titration or competition, vary from 104 to 108 M-1 for the 
series of complexes.  Significantly, binding affinities are found to be inversely related to 
ancillary ligand size and directly related to differential inhibition of the HCT116 cell 
lines.  The observed trend in binding affinity is consistent with the metalloinsertion mode 
where the complex binds from the minor groove with ejection of mismatched base pairs.  
The correlation between binding affinity and targeting of the MMR-deficient cell line 
suggests that rhodium metalloinsertors exert their selective biological effects on MMR-
deficient cells through mismatch binding in vivo. 
In particular, rhodium metalloinsertors bearing dipyridylamine ancillary ligands 
are shown to exhibit accelerated cellular uptake.  This increased uptake allows us to 
observe additional cellular responses to these agents, including disruption of the cell 
cycle, monitored by flow cytometry assays, and induction of necrosis, monitored by dye 
exclusion and caspase inhibition assays, that also occur preferentially in the HCT116O 
cell line.  Finally, these cellular responses provide insight into the mechanisms 
underlying the selective activity of this novel class of targeted anti-cancer agents, and are 
consistent with the idea that repair proteins are activated in response to DNA mismatch 
binding. 
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 1 
Introduction 
1.1 Deoxyribonucleic acid (DNA) 
DNA is the stuff of life. The anti-parallel double helix comprises two strands of the bases 
adenine (A), thymine (T), cytosine (C), and guanine (G) connected by the sugar-
phosphate backbones (figure 1.1).1 The sequence of these bases encodes the genetic 
information of the cell, and the pairings of bases between the strands follow simple rules 
for complementarity revealed by Watson, Crick, and Franklin over 60 years ago: A pairs 
with T, and C pairs with G.  The pairings between the bases are mediated by hydrogen 
bonds, with AT pairs forming two bonds while CG pairs form three bonds.  The double 
helix is further stabilized by π-stacking interactions between adjacent pairs of the 
aromatic bases. 
 Just three years later, Kornberg identified DNA polymerase I as the enzyme 
responsible for the template-directed synthesis of DNA in E. coli.2 Meselson and Stahl 
showed that DNA replication occurs through a semi-conservative mechanism wherein the 
double helix separates, and each old strand serves as the template for a new strand, 
yielding two duplexes that each contain one strand from the parent molecule.3 As a 
consequence of this mechanism, errors on either strand are converted to permanent 
mutations when the strands are copied.  Thus, DNA polymerase δ and DNA polymerase 
ε, the main human replicative polymerases, must replicate the genome with the greatest 
possible fidelity.4 
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Figure 1.1 Deoxyribonucleic acid (DNA). 
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Three factors contribute to accuracy of replication.5 The hydrogen bonding 
complementarity between the template and the next deoxyribonucleotide triphosphate 
(dNTP) to be added to the newly growing DNA provides an error rate of 1 in 104 bases, 
which is clearly insufficient. The proofreading domain of DNA polymerase has evolved 
to check the newly incorporated base immediately, lowering the error rate to 1 in 107-108 
bases, an impressive level of accuracy.  However, the human genome contains over 3 
×109 base pairs; thus, on the order of 102-103 errors are made during each cycle of DNA 
replication that result in incorrectly paired bases, termed DNA mismatches (figure 1.2).  
These mismatches are corrected by a different set of enzymes termed the mismatch repair 
pathway (MMR, figure 1.3).  MMR further reduces the error rate of DNA replication to 1 
in 109-1010 bases, affording essentially error-free duplication of the human genome under 
normal circumstances.6 
In addition to replication errors, DNA mismatches can arise naturally from other 
cellular processes.  Translesion synthesis occurs when error-prone polymerases, such as 
DNA polymerase ζ or DNA polymerase η, are utilized to replicate chemically damaged 
DNA, which is not an acceptable template for the high fidelity polymerases.7 Genetic 
recombination is an essential process in which homologous DNA sequences are 
exchanged between two DNA molecules, but the process generates mismatches when the 
sequences exchanged are not identical.8 Spontaneous deamination converts cytosine to 
uracil, resulting in GU mismatches that must be corrected before replication.9 Finally, B 
lymphocytes undergo somatic hypermutation, generating mismatches that increase the 
diversity of antibodies.10 With the exception of somatic hypermutation, mismatches 
arising from all of these processes are detected and repaired by MMR.   
 4 
 
 
 
 
 
 
Figure 1.2. DNA mismatches.  In well-matched DNA, bases pair according to Watson-
Crick hydrogen bonding rules: A pairs with T and C pairs with G (top row).  Alternative 
base pairings are termed DNA mismatches (AA, GA, GG, AC, GT, TT, TC, CC).  
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1.2 Mismatch repair 
The mismatch repair (MMR) pathway corrects DNA mismatches, as well as 
insertion/deletion loops that arise during DNA synthesis, increasing the fidelity of DNA 
replication by a factor of 50-1000.11 The pathway is best characterized in E. coli and is 
shown schematically in figure 1.3.  Mismatches are first recognized by the MutS dimer, 
which then recruits the MutL dimer. The MutS-MutL complex in turn activates MutH, an 
endonuclease specific for the sequence GATC.  Newly synthesized DNA strands in E. 
coli are unmethylated at these sites, and thus hemimethylation of the duplex provides the 
strand discrimination signal to direct the nicking activity of MutH.  After scission a long 
patch, between 1,000–2,000 bases, is removed by the combined action of DNA helicase 
II and any one of several exonucleases. DNA polymerase fills the gap left by the excised 
strand, and the nicks surrounding the newly synthesized DNA are closed by DNA ligase.  
Several homologues of the MMR proteins exist in eukaryotes.  Six homologues of MutS 
(MSH1-6) and four homologues of MutL (MLH1, MLH3, PMS1, and PMS2) have been 
identified; of these, MSH2 and MLH1 have been shown to be essential for MMR in 
humans.12 
Not surprisingly, as uncorrected mismatches are converted to mutations in 
subsequent cycles of DNA replication, cells with MMR deficiencies exhibit elevated 
mutation rates.13-15 Germline mutations in MLH1 or MSH2 dramatically increase the risk 
of developing hereditary nonpolyposis colon cancer (HNPCC), the most common type of 
inherited colon cancer.16,17  HNPCC is marked by early onset and the presence of cancers 
in several other tissue types.17  Roughly 15% of sporadic colorectal cancer cases have 
also been linked to MMR deficiency.18  Epigenetic silencing of the MMR genes has been 
identified as the cause of MMR deficiency in these cases.19  
 6 
 
 
 
 
Figure 1.3. The mismatch repair (MMR) pathway in E. coli. 
  
 7 
In addition to colorectal cancer, mismatch repair deficiencies have been found in 
approximately 16% of solid tumors of all tissue types.14,20 
Importantly, MMR deficiency confers resistance or tolerance to many of the anti-
cancer agents currently in clinical use.21,22  Alkylation by the commonly used 
chemotherapeutic agents N-methyl-N-nitrosourea (MNU) and N-methyl-N´-nitro-N-
nitrosoguanidine (MNNG) at the O6 position of guanine nucleotides triggers an apoptotic 
response after recognition of O6-meG:C and O6-meG:T base pairs by the MMR 
pathway, while MMR-deficient cells tolerate this DNA methylation.21-23  Failure to 
recognize DNA adducts is also involved in the resistance of MMR-deficient cells to the 
platinum compounds cisplatin and carboplatin.21-24  The incorporation of anti-metabolites 
such as 5-fluorouracil and 6-thioguanine into DNA triggers cell cycle arrest and apoptosis 
through the MMR pathway, and consequently MMR-deficient cells are resistant to these 
agents as well.25,26  Other studies have shown low-level resistance to the type I 
topoisomerase poisons camptothecin and topotecan in MLH1 deficient lines and to the 
type II topoisomerase poisons doxorubicin, epirubicin, and mitoxantrone in MLH1 or 
MSH2 deficient lines.27  It has been hypothesized that treatment regimens with agents 
such as cisplatin might enrich tumors for MMR-deficient cells28 and has been shown that 
roughly half of secondary, or therapy-related, leukemias show signs of MMR 
deficiency.28,29 Collectively, these results show the broad involvement of MMR in 
mediating drug response to DNA-targeted agents, the effects of MMR deficiency on this 
response, and the need to develop therapeutic agents that specifically target MMR-
deficient cells. 
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Figure 1.4. X-ray crystal structures of some DNA mismatches.  The mismatched base 
pairs (red) do not significantly perturb the structure of the DNA duplex or differ 
noticeably from the well-matched base pairs (white).36-40 
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1.3 Mismatch Recognition by Rhodium Metalloinsertors 
Previous work in our laboratory focused on tris(chelate) rhodium complexes that 
intercalated in well-matched DNA, such as [Rh(bpy)2phi]3+ (bpy = 2,2’-bipyridine; phi = 
9,10-phenathrenequinonediimine).30 These mononuclear, d6 octahedral complexes are 
coordinately saturated and inert to substitution, making them resistant to decomposition 
under physiologically relevant conditions. While the phi ligand is responsible for DNA 
binding, judicious introduction of functional groups on the ancillary ligands confers 
sequence specificity on the complexes, such as Δ-α-[Rh{(R,R)-Me2trien}(phi)]3+, which 
recognizes 5’-TGCA-3’.31 
These complexes have since been adapted to target DNA mismatches in vitro.32-34 
Because DNA mismatches fail to obey Watson-Crick rules for hydrogen bonding, they 
are destabilized relative to well-matched DNA.  The relative stability of mismatches has 
been studied extensively by UV-Vis and NMR, and it is widely accepted that base pair 
stability follows the sequence CG > AT > > GG ~ GT ~ AG > > TT ~ AA > CT ~ AC > 
CC.35 It is this thermodynamic destabilization that our laboratory seeks to exploit as a 
means of targeting mismatches, since mismatches do not significantly perturb the 
structure of the B-form DNA duplex (figure 1.4).36-40  By expanding the aromatic system 
of the phi ligand to make the tetracyclic chrysi ligand (chrysi = chrysene-5,6-
quinonediimine, figure 1.5), the width of the DNA binding ligand increases from 9.2 Å to 
11.3 Å, thus exceeding the width of well-matched base pairs, 10.8 Å for both AT and 
CG.   As a result, complexes bearing the chrysi ligand can only be accommodated by 
DNA at thermodynamically destabilized mismatch sites. 
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Figure 1.5 Design of a mismatch recognition agent. Extension of the aromatic system 
of the phi ligand to the bulkier chrysi ligand increases the width of the complex beyond 
the width of well-matched DNA, 10.8 Å for either base pair, and restricts binding to 
thermodynamically destabilized mismatched sites within the DNA duplex. 
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In addition to their DNA binding capabilities, these complexes also promote 
single-stranded cleavage of the DNA backbone upon photoactivation.  This provides a 
useful tool to probe DNA binding.  Photocleavage titration experiments revealed that the 
first generation compound, [Rh(bpy)2chrysi]3+, binds 80% of DNA mismatches with 
typical binding constants of 106 M-1 and remarkable specificity for mismatched DNA; 
similar experiments also showed specific targeting of the mismatch in a 2.7 kb DNA 
fragment.32,33  Subsequent work led to the incorporation of nitrogen atoms into the 
intercalating ligand and a 50-fold increase in binding affinity for the second compound, 
[Rh(bpy)2phzi]3+ (phzi = benzo[a] phenazine-5,6-quinonediimine).34 
A high resolution crystal structure of [Rh(bpy)2chrysi]3+ bound to single base 
mismatches within a DNA oligonucleotide duplex reveals a distinctive binding mode at 
the mismatched site.41  We had previously demonstrated that rhodium intercalators 
bearing the phi ligand bind to well-matched DNA by partial intercalation of the planar 
phi ligand from the major groove side into the base pair stack.31  However, binding to the 
mismatched site involves instead insertion of the more expansive chrysi ligand into the 
DNA duplex from the minor groove side at the mismatched site with ejection of the 
mismatched bases out of the DNA stack; the inserted ligand stacks fully with adjacent 
base pairs (figure 1.6, left).  NMR studies confirm this metalloinsertion mode for the 
complex at mismatched sites in solution.42 Further crystallographic studies revealed the 
generality of the metalloinsertion binding mode; in independent views of metalloinsertion 
at four different mismatch sites, the ejected bases superimpose identically (figure 1.6, 
right).43 
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Figure 1.6 Metalloinsertion is a novel binding mode.  Left: The metal complex 
approaches the duplex from the minor groove, ejecting the mismatched bases (A, C) from 
the helix and replacing them with the chrysi ligand, which stacks fully with the adjacent 
base pairs.41 Right: Superposition of four independent crystallographic views reveals the 
generality of the metalloinsertion binding mode.43 
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Target binding alone is insufficient to ensure biological activity in a cellular 
context; cellular accumulation is also a prerequisite, and several possible avenues exist 
for metalloinsertors to gain entry to the cell.44 Uptake can occur by energy-dependent 
processes, such as active transport or endocytosis, by facilitated diffusion through ion 
channels, or by passive diffusion across the plasma membrane (figure 1.7).  Confocal 
microscopy and flow cytometry studies have been performed to determine the method of 
uptake for tris(chelate) luminescent ruthenium complexes.45,46  Metabolic inhibition 
either by incubation at low temperature or by treatment with deoxyglucose and 
oligomycin had no effect on ruthenium accumulation within HeLa cells.  This result 
clearly eliminated any active mode of uptake from consideration.  Similarly, fluorescence 
levels were not affected by pre-incubation with a panel of organic cation transporter 
(OCT) inhibitors.  Although other ion channels may not have been targeted by the 
inhibitors, these data argue against facilitated diffusion.  Ultimately, uptake was shown to 
depend on membrane potential; hyperpolarization with valinomycin increased mean 
cellular fluorescence while depolarization with high potassium buffer decreased cellular 
fluorescence.  As a whole, these data provide strong evidence that passive diffusion 
driven by the membrane potential is the most likely route of cellular uptake for these 
cationic complexes.  In addition, variations in the ancillary ligands have dramatic effects 
on cellular uptake, with increased lipophilicity facilitating uptake; this is consistent with 
diffusion across the lipid bilayer of the plasma membrane.  By analogy, it is likely that 
rhodium metalloinsertors also accumulate within cells via passive diffusion.  For both 
rhodium and ruthenium complexes, it has also been shown that uptake can be increased 
through functionalization with a nuclear localizing peptide.47,48  
 14 
 
 
 
 
 
 
 
 
Figure 1.7 Modes of cellular uptake.44 
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 Taken together, the observations that (i) rhodium metalloinsertors are capable of 
recognizing mismatches with high selectivity and (ii) analogous ruthenium complexes 
accumulate within cells and nuclei form a sound basis for the hypothesis that rhodium 
metalloinsertors recognize mismatched DNA within cells.  Furthermore, the unique 
geometry of the metalloinsertion binding mode, where the mismatched bases are ejected 
by the metal complex into extrahelical space, suggests that recognition would likely 
trigger a cellular response.   Finally, the approximately 1,000-fold greater number of 
mismatches within MMR-deficient cells affords a means of discrimination as a function 
of MMR status, affording rhodium metalloinsertors the opportunity to act as targeted 
therapeutic agents.  The studies described herein constitute the first steps in translating 
the development of these complexes from in vitro, molecular models of mismatch 
recognition to in cellulo models of mismatch targeting in MMR-deficient human 
carcinoma cell cultures. 
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Chapter 2: Anti-proliferative effects of 
[Rh(bpy)2chrysi]
3+ and [Rh(bpy)2phzi]
3+  
 
Note: This chapter was adapted from “DNA mismatch-specific targeting and 
hypersensitivity of mismatch-repair-deficient cells to bulky rhodium(III) intercalators.” 
J.R. Hart, O. Glebov, R.J. Ernst, I.R. Kirsch, and J.K. Barton. J. Am. Chem. Soc. 2006, 
103, 15359-15363 
2.1. Introduction 
We have developed bulky rhodium metalloinsertors (figure 2.1) that bind single base 
mismatches in DNA selectively and irrespective of sequence context.1-4  These 
compounds bind the mismatch by intercalation and, upon photoexcitation, promote strand 
breaks at the mismatched site. [Bis(2,2’-bpipyridine)(chrysene-5,6-
quinonediimine)Rh(III)], [Rh(bpy)2(chrysi)]3+, binds mismatches with moderate affinity 
and high specificity.  The site-specificity depends upon the thermodynamic instability 
associated with a base pair mismatch; the bulky intercalator cannot stack easily within 
well-matched DNA but can more easily insert neighboring a destabilized mismatched 
site. The high specificity of [Rh(bpy)2chrysi]3+ is well demonstrated in its ability to 
cleave a single mismatched site in a 2700 base pair duplex.2  This specificity has been 
used advantageously in a site-specific assay for single nucleotide polymorphisms in 
pooled genomic DNA.5  Our second generation complex [bis(2,2’-
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bpipyridine)(benzo[a]phenazine-5,6,-quinonediimine)Rh(III)], [Rh(bpy)2(phzi)]3+, 
utilizes heterocyclic nitrogens within the bulky intercalating ligand to boost the affinity of 
the complex for mismatched sites.4  [Rh(bpy)2phzi]3+ is capable of binding mismatched 
sites with 100 nM affinity and similar specificity to [Rh(bpy)2chrysi]3+. 
Importantly, both of these complexes have been applied in probing whether 
MMR-deficient cells accumulate mismatches.4 In photocleavage assays of genomic DNA 
from a series of cell lines, some proficient in mismatch repair and others wholly or 
partially deficient in repair, a clear correlation between photocleavage by 
[Rh(bpy)2chrysi]3+and [Rh(bpy)2phzi]3+ and MMR deficiency was evident.  
Here we explore the efficacy of these rhodium complexes in inhibiting the growth 
of MMR-deficient versus MMR-proficient cell lines in the presence and absence of 
photoactivation. The biological effects are assessed in two cell lines, both of which are 
derivatives of HCT116.  These cell lines have had an extra copy of either chromosome 2, 
HCT116O, or 3, HCT116N, inserted in the cell; placing a copy of chromosome 3 within 
this cell line corrects the mismatch repair deficiency by introducing a functional copy of 
the MLH1 gene with a normal promoter.6 Additionally, mouse fibroblast cells derived 
from litter mates which are Msh2- or Msh2+ were also studied. These cells and cell lines 
provide a convenient method for testing whether a particular compound will differentially 
target MMR-deficient cells, because these cells are essentially identical genetically, 
except with regard to mismatch repair.   
2.2. Experimental Protocols 
2.2.1 Materials 
Media and supplements were purchased from Invitrogen (Carlsbad, CA).  5-
bromodeoxyuridine (BrdU), antibodies, buffers and peroxidase substrate were purchased 
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in kit format from Roche Molecular Biochemicals (Mannheim, Germany).  Irradiations 
were performed with an Oriel (Darmstadt, Germany) 1,000 W Hg/Xe solar simulator 
using a UVB/C blocking filter. 
2.2.2 Synthesis of Metal Complexes 
Rac-[Rh(bpy)2(chrysi)]Cl3 and rac-[Rh(bpy)2(phzi)]Cl3 were synthesized using 
established procedures.1,4  Rac-[Rh(bpy)2(chrysi)]Cl3 was resolved into Δ and Λ isomers 
using potassium antimonyl tartrate as previously described.7  Salts were exchanged to 
chloride before use using Sephadex QAE ion exchange resin. 
2.2.3 Cell lines, Media, and Culture 
The HCT116N and HCT116O cell lines were obtained from Bert Vogelstein (The Johns 
Hopkins University, Baltimore, MD) and were originally derived from the laboratory of 
C.R. Boland (University of California at San Diego, La Jolla, CA).6  Cells were grown in 
RPMI-1640 media supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 0.1 
mM non-essential amino acids, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 ug/ml 
streptomycin, 400 ug/ml geneticin (G418).  Cells were grown in tissue culture flasks and 
dishes (Corning Costar, Acton, MA) at 37 °C under 5% CO2 atmosphere. Mouse 
fibroblasts were obtained as previously reported and established for heterozygous and 
homozygous littermates and used at passages 5 and 6.8 Cells were grown in DMEM with 
media as for HCT116 cells. 
2.2.4 Cell proliferation assays 
Cell proliferation was measured using the 5-bromouracil incorporation assay (figure 
2.2).9  Cells were plated in 96 well plates at 2000 cells/well and grown for 24 hours.  At 
this point, variable concentrations of rhodium complexes were added.  The cell cultures 
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were then allowed to grow for 48 hours or 6-96 hours as indicated.  Cells were then either 
irradiated or not followed by the addition of 5-bromodeoxyuridine, BrdU.  Irradiations of 
cells were performed using a solar simulator adapted for irradiation from the bottom of 
the well plates.  The cells were grown for an additional 24 hours.  The BrdU 
incorporation was assayed by antibody assay using established procedures.9 
2.2.5 Photocleavage of mismatched DNA with rhodium isomers 
Photocleavage experiments were conducted on the 436-mer PCR product as described in 
detail earlier5 but using 500 nM of the purified isomers, Δ- or Λ-[Rh(bpy)2chrysi]3+. 
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Figure 2.1. Structures of  (top) Λ- (left) and Δ- (right) [Rh(bpy)2chrysi]3+ and (bottom) 
Δ-[Rh(bpy)2phzi]3+. 
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Figure 2.2. Enyzme-linked immunosorbent assay for BrdU incorporation 
(ELISA).9 Cells are plated at a density of 2 x 103 cells/well and treated with varying 
concentrations of rhodium complex.  Before analysis, cells are labeled with BrdU for 24 
hours.  The amount of BrdU incorporated during DNA synthesis can then be quantified 
with an enzyme-conjugated antibody and a chromogenic substrate. 
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2.3. Results 
2.3.1 Preferential inhibition of cellular proliferation 
The HCT116 derived cells were treated with either [Rh(bpy)2chrysi]3+or [Rh(bpy)2phzi]3+ 
for 96 hours at varying concentrations in the absence of irradiation. As is evident for both 
complexes (figure 2.3), we see a significant inhibition of cell proliferation.  Importantly, 
for both complexes we also see a preferential inhibition in the MMR-deficient strain.  
This selectivity seen with the rhodium complexes for the MMR-deficient HCT116O 
contrasts the action, also shown, of N-methyl, N’-nitro-nitrosoguanidine (MNNG), a 
common DNA-methylating agent, that is found to be more toxic to the MMR-proficient 
cell line, HCT116N.6  MNNG is typical of most chemotherapeutics that target genomic 
DNA.   
Experiments using mouse fibroblasts that are deficient for MMR, Msh2-, or 
proficient for MMR, Msh2+, were also performed.  These experiments complement those 
conducted with HCT116, because the cells also are genetically identical except for the 
Msh2 gene.  Experiments probing these fibroblast cells, which are not cancerous, 
therefore provide a rigorous test that targets MMR-deficiency.  The data given in figure 
2.4 show that the MMR-defective mouse embryo fibroblasts that are Msh2- yield 
decreased DNA synthesis and are therefore more sensitive to [Rh(bpy)2phzi]3+ compared 
with the control littermate cells that are Msh2+.  These results parallel those obtained with 
the HCT116 model system.  These results furthermore provide strong support for the idea 
that the inhibition of cell proliferation is related to the MMR-deficiency of the cell, 
regardless of which mismatch repair gene is absent. 
The effect of incubation time was also investigated, and the results are shown in 
figure 2.5.  Cells were exposed to variable concentrations of [Rh(bpy)2chrysi]3+for 
 26 
varying amounts of time from 6 hour to 96 hours, before testing the effects on DNA 
synthesis.  In this series, it is clear that the maximum effect is obtained after 48 hours of 
incubation.  Based upon studies with analogous ruthenium complexes10,11, we believe 
cellular uptake to be rate-limiting; indeed, with more hydrophobic chrysi analogues, we 
find differential biological effects with much shorter incubation times (Chapter 3). 
Significantly, the results seen here with the bulky rhodium complexes are 
distinctive, in contrast with common therapeutics and MNNG.  MMR-deficient cell lines 
are generally resistant to the majority of alkylating drugs, platinum compounds, and 
metabolic analogues, because the antiproliferative effects these therapeutic agents have 
on cancerous cells are due in part to recognition of the drug-induced genomic DNA 
damage by the MMR system.12,13  In contrast, we find with the rhodium complexes the 
preferential inhibition of cellular proliferation in cells that depends strictly on their 
deficiency in MMR.   
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Figure 2.3. Differential antiproliferative effect of rac-[Rh(bpy)2chrysi]3+ , rac-
[Rh(bpy)2phzi]3+, and MNNG on MMR-deficient (red) and MMR-proficient (green) cell 
lines.  Cell lines derived from the HCT116 cell line were treated with the methylating 
agent MNNG, [Rh(bpy)2chrysi]3+, or [Rh(bpy)2phzi]3+ as described in Experimental 
Protocols.  Note that the MMR-deficient population HCT116O is resistant to the action of 
MNNG but is sensitive preferentially to [Rh(bpy)2chrysi]3+ and [Rh(bpy)2phzi]3+.  
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Figure 2.4. Antiproliferative effect of rac-[Rh(bpy)2phzi]3+  on MMR-deficient 
(Msh2-, red) and MMR-proficient (Msh2+, green) mouse embryonic fibroblasts.  The 
preferential inhibition of DNA synthesis parallels the effects seen with the HCT116 cell 
lines.  
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Figure 2.5. Effect of varying drug incubation time on cell proliferation.  HCT116O 
cells that are MMR-deficient (red) and HCT116N cells that are MMR-proficient (green) 
were exposed to varying concentrations of rac-[Rh(bpy)2chrysi]3+ for different incubation 
times as shown.  Antiproliferative effects increase with longer incubation times up to 48 
hours. 
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2.3.2 Correlations between biological effects and DNA mismatch targeting 
In an effort to correlate the biological effects we observed by using these bulky 
metalloinsertors with their DNA binding characteristics, experiments were conducted 
also using enantiomers of [Rh(bpy)2chrysi]3+.  Only the Δ-isomer of [Rh(bpy)2chrysi]3+ 
binds and cleaves, with photoactivation, a neighboring mismatched DNA site.1  Shown in 
figure 2.6 is an illustration of the enantiospecific reaction of [Rh(bpy)2chrysi]3+ at a 
single CC mismatch on a  436-mer DNA duplex PCR product containing a single CC 
mismatch.  As illustrated in the capillary gel electrophoresis results, upon photolyis of the 
complex bound to DNA, the bulky Δ-isomer cleaves the DNA neighboring the 
destabilized mismatch.  No cleavage is seen without metal complex (light control) or 
after photolysis using the Λ-isomer.  In general, surveying different mismatched sites in a 
variety of sequence contexts, we have found the recognition to be enantioselective; it is 
Δ-[Rh(bpy)2chrysi]3+ that binds and cleaves mismatched DNA preferentially.3 
We therefore also compared the antiproliferative effects of the two isomers 
(Figure 2.7).  Consistent with DNA targeting studies, it is Δ-[Rh(bpy)2chrysi]3+ that 
shows selective inhibition of cellular proliferation in the MMR-deficient HCT116O cell 
line. At 5 µM rhodium, incubation with Λ-[Rh(bpy)2chrysi]3+ shows no effect on DNA 
synthesis in either HCT116O or HCT116N cells, whereas the Δ-isomer selectively 
inhibits DNA synthesis in the MMR-deficient HCT116O cells.  Although these rhodium 
complexes are coordinatively saturated and generally inert to substitution, we had 
considered the possibility that the biological activity of the complexes might be 
associated with complex decomposition and ligand release.  The finding of high 
enantioselectivity associated with the biological effect argues against complex 
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decomposition as being responsible for the inhibition of cellular proliferation, since a 
similar decomposition would be likely for both isomers.    
Because the complexes bind mismatched DNA only non-covalently in the 
absence of light, but with photolysis, promote DNA strand breaks, we also explored cell 
proliferation assays after exposing the cells to compound and light, conditions under 
which the rhodium complex might be expected to be more potent.  We therefore 
irradiated cells for 10, 15, or 20 minutes after 48 h incubation with the rhodium complex.  
These results are shown in figure 2.8.  Here it should be noted that longer periods of 
irradiation even without metal complex lead to some inhibitory effects in both MMR-
deficient and MMR-proficient cell lines; evaporation of the medium is also somewhat of 
a problem.  Nonetheless, light activation over short periods does indeed lead to greater 
inhibition of cell proliferation and only for Δ-[Rh(bpy)2chrysi]3+ in the mismatch repair 
deficient HCT116O cells.   Again, parallel experiments with Λ-[Rh(bpy)2chrysi]3+ 
provide a useful control.  Under the conditions utilized, light activation appears to 
enhance the inhibition of DNA synthesis preferentially by Δ-[Rh(bpy)2chrysi]3+ and only 
in the MMR-deficient HCT116O cells.  These data are consistent with DNA serving as 
the target for the rhodium complex inside the cell.  Certainly these results demonstrate a 
clear correlation between mismatch targeting by rhodium photocleavage and biological 
potency in a cell-selective manner. 
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Figure 2.6. Effect of stereoisomers on photocleavage.  Shown are capillary 
electropherograms after photolysis of 436-mer PCR products containing a single CC 
mismatch with 500 nM Λ -(middle) or Δ -(bottom) [Rh(bpy)2chrysi]3+, as described 
earlier.3  Mismatch-specific photocleavage to produce a 170 base fragment is evident 
only with the Δ-isomer. 
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Figure 2.7. Antiproliferative effects of different stereoisomers of Rh(bpy)2chrysi3+.  
Shown are the effects on BrdU incorporation in HCT116O (red) and HCT116N (green) 
cells after 48 h incubation without with 5µM Λ- or Δ-[Rh(bpy)2chrysi]3+.  The selective 
inhibition of the mismatch repair deficient HCT116O cell line is seen only with the Δ-
isomer. 
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Figure 2.8. Antiproliferative effect of different stereoisomers of Rh(bpy)2chrysi3+ 
with irradiation.  Shown are the effects of varying amounts of irradiation of HCT116O 
cells in the absence of [Rh(bpy)2chrysi]3+ (black), in the presence of 5µM Δ- 
[Rh(bpy)2chrysi]3+ (red) or Λ-[Rh(bpy)2chrysi]3+ (blue) after 48 h incubation. 
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2.4. Discussion 
The results reported here establish that the bulky rhodium metalloinsertors serve as 
inhibitors of cellular proliferation and, significantly, that the complexes do so with 
cellular selectivity.  Biological effects are seen preferentially in MMR-deficient cells. 
These results do not establish DNA mismatch targeting as the basis for the cell 
selectivity.  However, these data are consistent with mismatched DNA being the target of 
these complexes, and hence the basis of the preferential reaction in MMR-deficient cell 
lines, in which mismatches are more abundant. 
It is noteworthy that in the absence of light, the complexes bind DNA mismatches 
non-covalently, albeit with high affinity and specificity.  Because a covalent adduct is not 
formed and, in the absence of light, no DNA damage is directly generated, any biological 
effect would be expected to be more modest; irradiation, which does cause DNA strand 
breaks, should enhance the effect, as we observe.  Likely, then, without light the metal-
mismatch complex provides a secondary signal for protein binding or activation. It 
should also be noted that light activation of the metal complex generates only a short 
lived ligand radical; thus, intimate association of the rhodium complex with its target is 
needed for a light dependent reaction.14 
Significantly, the biological effects we observe in MMR-deficient cells also are 
enantiospecific, just as binding of the bulky rhodium metalloinsertors at mismatched 
DNA sites is enantiospecific.  It is the Δ-isomer of [Rh(bpy)2chrysi]3+ that binds and 
selectively cleaves a neighboring base pair mismatch, and it is the Δ-isomer that shows 
the biological effect preferentially in MMR-deficient cells. 
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2.5. Conclusions 
There is a clear correlation if not an established causality between DNA mismatch 
targeting by the rhodium complexes and the observed inhibition of cellular proliferation 
in MMR-deficient cells. These results therefore highlight a new class of compounds for 
possible application in cancer therapeutics.  The work furthermore underscores a cell-
selective strategy in chemotherapeutic design by chemically and site-specifically 
targeting DNA mismatches. 
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Chapter 3: DNA Mismatch Binding and Anti-
Proliferative Effects of Rhodium Metalloinsertors 
 
Note: This chaper was adapted from “DNA mismatch binding and anti-proliferative 
effects of rhodium metalloinsertors.” R.J. Ernst, H.G. Song, and J.K. Barton. J. Am. 
Chem. Soc. 2009, 131, 2359-2366. 
 
3.1. Introduction 
Recent work within our laboratory on luminescent ruthenium dppz complexes has shown 
that these tris(chelate) complexes are taken up inside cells through passive diffusion 
facilitated by the membrane potential.28,29  Variations in ancillary ligands of these 
ruthenium complexes have dramatic effects on cellular uptake, with increased 
lipophilicity facilitating uptake.  Here we examine the effects of ancillary ligand variation 
in the Rh(L)2chrysi3+ family (figure 3.1) on the ability of these complexes to target DNA 
mismatches in vitro and in vivo.  Rhodium metalloinsertors bearing ammine, 2,2-
bipyridine (bpy), 9,10-phenanthroline (phen), 1,4-diphenylphenanthroline (DIP), and 2,2-
dipyridylamine (HDPA) ancillary ligands were synthesized.  Their mismatch targeting 
capabilities were determined by photocleavage titration and cellular proliferation assays.   
Importantly we establish that the differential inhibition of cellular proliferation in MMR-
deficient cells is correlated with mismatch binding affinity.   
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Figure 3.1. Rh(L)2chrysi3+ family of metalloinsertors. 
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3.2. Experimental Protocols 
3.2.1 Materials 
RhCl3 was purchased from Pressure Chemical, Inc. (Pittsburgh, PA).  [Rh(NH3)5Cl]Cl2 
was obtained from Strem Chemical, Inc. (Newburyport, MA).  2,2'-dipyridylamine 
(HDPA), 4,7-diphenyl-1,10-phenanthroline (DIP), and Sephadex ion exchange resin were 
obtained from Sigma-Aldrich (St. Louis, MO).  Sep-Pak C18 solid phase extraction 
cartridges were purchased from Waters Chemical Co. (Milford, MA).  Phosphoramidites 
were purchased from Glen Research (Sterling, VA).  Media and supplements were 
purchased from Invitrogen (Carlsbad, CA).  BrdU, antibodies, buffers, and peroxidase 
substrate were purchased in kit format from Roche Molecular Biochemicals (Mannheim, 
Germany).  All commercial materials were used as received. 
3.2.2  Oligonucleotide Synthesis 
Oligonucleotides were synthesized on an Applied Biosystems 3400 DNA synthesizer 
using standard phosphoramidite chemistry. DNA was synthesized with a 5'-dimethoxy 
trityl (DMT) protecting group.  The oligonucleotides were cleaved from the beads by 
reaction with concentrated ammonium hydroxide at 60°C overnight.  The resulting free 
oligonucleotides were purified by HPLC using a C18 reverse-phase column (Varian, Inc.) 
on a Hewlett-Packard 1100 HPLC.  The DMT group was removed by reaction with 80% 
acetic acid for 15 min at room temperature.  The DMT-free oligonucleotides were 
precipitated with absolute ethanol and purified again by HPLC.  Positive identification of 
the oligonucleotides and their purity were confirmed by MALDI-TOF mass 
spectrometry. Quantification was performed on a Beckman DU 7400 spectrophotometer 
using the extinction coefficients at 260 nm (ε260) estimated for single stranded DNA. 
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3.2.3  Synthesis and Characterization of Metal Complexes 
Chrysene-5,6-dione, [Rh(bpy)2chrysi]Cl3  and [Rh(phen)2chrysi]Cl3 were prepared 
according to previously reported procedures.19,20,31  Rhodium complexes were prepared 
by one of two synthetic routes; the first is shown in figure 3.2.  Two equivalents of 
ancillary ligand are added to RhCl3.  The remaining two chlorides are then exchanged for 
ammine ligands through a triflate intermediate as described by Sargeson and 
coworkers.32,33 Lastly, the chrysi ligand is installed by condensing the quinone onto the 
ammines.  This is the standard approach for the bpy, phen, and DIP complexes.  
Alternatively, the route shown in figure 3.3 may be taken.  Here, the commercially 
available chloropentammine complex is converted to the hexaammine complex, again as 
described by Sargeson. 32,33 The chrysi ligand is then installed by the condensation 
reaction as before, and finally the chelating ancillary ligands are substituted for the 
remaining four ammine ligands.  This pathway is taken for the tetraammine and HDPA 
complexes. 
[Rh(NH3)4chrysi]OTf3: [Rh(NH3)6]OTf3 was prepared as described by 
Sargeson.32,33 [Rh(NH3)6]OTf3 was reacted with a limiting amount of chrysene quinone in 
a 3:1 acetonitrile:water mixture with excess sodium hydroxide as a catalyst to form 
[Rh(NH3)4chrysi]OTf3.  Acetonitrile was removed in vacuo, followed by filtration to 
remove unreacted chrysi quinone.  The product was separated from unreacted 
[Rh(NH3)6]OTf3 by solid phase extraction on a C18 cartridge and eluted with 1:1:0.001 
acetonitrile:water:TFA. 1H NMR (d6-DMSO, 50°C, 300 MHz): δ 13.30 (s), 12.32 (s), 
8.876 (t, 1H, 7.7Hz), 8.787 (d, 1H, 7.9Hz), 8.57-8.51 (m, 2H), 8.358 (dd, 1H, 8.9Hz, 
4.6Hz), 8.145 (d, 1H, 7.7Hz), 7.85-7.70 (m,4H), 4.73-4.54 (broad m, 6H), 3.862 (s, 3H) 
ppm.  UV/vis (H2O, pH 5): 263 nm, (60,900 M-1cm-1), 283 nm (38,100 M-1cm-1), 326 nm 
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(12,600 M-1cm-1), 413 nm (12,000 M-1cm-1).  MALDI-MS (cation) 425 m/z (M-2H+) 
obs., 427 m/z calc. 
 [Rh(HDPA)2(chrysi)]OTf3: [Rh(NH3)4(chrysi)]OTf3 (15 mg, 0.02 mmol) was 
reacted with HDPA (20 mg, 0.12 mmol, excess) in 20 mL ethanol and 20 mL water.  The 
dark red solution was heated under reflux for 16 h. The reaction mixture turned reddish 
brown upon heating. Ethanol was removed under vacuum and the resulting solution 
filtered to remove any residue. The filtrate was concentrated on a Sep-Pak C18 cartridge 
eluting with 1:1:0.1% acetonitrile:water:TFA, lyophilized, and purified on an alumina 
column eluting with 2% methanol in dichloromethane.  The fractions were collected and 
dried under vacuum to give an orange-brown solid (8 mg, 39%). 1H-NMR (d6-DMSO, 
300 MHz): δ12.84 (s, 1H), 12.34 (s, 1H), 11.78 (s, 1H), 10.32 (d, 1H, 8.7Hz), 8.63 (d, 
1H, 6.9Hz), 8.40 (d, 1H, 8.4Hz), 8.31 (d, 1H, 9.3Hz), 8.14 (m, 2H), 8.07 (d, 1H, 8.7Hz), 
8.04 (d, 1H, 5.4Hz), 7.94 (m, 4H), 7.77 (m, 5H), 7.58 (m, 2H), 7.48 (d, 1H, 8.1Hz), 7.41 
(d, 1H, 8.4Hz), 7.32 (s, 1H), 7.14 (m, 2H), 7.04 (t, 1H, 6.8Hz), 6.98 (t, 1H, 6.9Hz), 6.81 
(t, 1H, 6.5Hz) ppm. UV/vis (H2O, pH 5): 287 nm (42,200 M-1cm-1), 321 nm (23,000 M-
1cm-1), 442 nm (8,800 M-1cm-1). ESI-MS (cation): 699.2 m/z (M-2H+), 350.1 m/z (M-
H2+) obs., 699.2 m/z (M-2H+) calc. 
 [Rh(DIP)2(NH3)2]OTf3:  RhCl3 and 2 equivalents of DIP were combined in 1:1 
ethanol:water and refluxed overnight.  The solvent was removed in vacuo and the product 
was recrystallized by dissolving in acetonitrile at 60°C and cooling to –20°C.  The 
precipitate was collected by filtration, washed in diethyl ether, and dissolved in neat 
triflic acid.  The solution was again cooled and added dropwise to NH4OH at –20°C.  The 
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pale white precipitate was collected by filtration and washed with a small amount of 
water to give [Rh(DIP)2(NH3)2]OTf3. 
 [Rh(DIP)2chrysi]Cl3:  [Rh(DIP)2(NH3)2]OTf3 was combined with a 10% excess of 
5,6-chrysenequinone and a catalytic amount of NaOH in acetonitrile and stirred at room 
temperature overnight.  The condensation was terminated by addition of a stoichiometric 
amount of HCl.  The solvent was removed in vacuo and the product was purified by 
alumina column chromatography.  Unbound chrysi ligand eluted first with ethyl acetate, 
and the purified product then eluted with acetonitrile.  Finally, the compound was 
dissolved in 3:2 MeCN:H2O and the triflate counterion was exchanged for chloride ion 
with Sephadex QAE-125 ion exchange resin. UV/vis (H2O, pH 5): 290 nm (104,000 M-
1cm-1); 335 nm (43,900 M-1cm-1); 373 nm (22,300 M-1cm-1). ESI-MS (cation): 1020.9 m/z 
(M-2H+), 511.0 m/z (M-H2+) obs., 1023 calc. 
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Figure 3.2. Rh(L)2chrysi3+ synthetic route I. 
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Figure 3.3. Rh(L)2chrysi3+ synthetic route II. 
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3.2.4 Photocleavage Titrations 
The oligonucleotide was 32P-labeled at the 5'-end by incubating DNA with 32P-ATP and 
polynucleotide kinase (PNK) at 37°C for 2 h, followed by purification using gel 
electrophoresis.  A small amount of the labeled DNA (less than 1% of the total amount of 
DNA) was added to 2 µM DNA in 100 mM NaCl, 20 mM NaPi, pH 7.1 buffer.  The 
DNA hairpin was annealed by heating at 90°C for 10 min and cooling slowly to room 
temperature over a period of 2 h.  Racemic rhodium complex solutions ranging from 
nanomolar to micromolar concentration were made in Milli-Q water. Annealed 2 µM 
DNA (10 µL) and 10 µL of Rh solution at each concentration were mixed in a 
microcentrifuge tube and incubated at 37°C for 10 min.  A light control (LC), in which 
the DNA was mixed with 10 µL of water and irradiated, and a dark control (DC), in 
which the DNA was mixed with the highest concentration of rhodium complex without 
irradiation, were also prepared.  The samples were left in the heat block and irradiated on 
an Oriel (Darmstadt, Germany) 1000 W Hg/Xe solar simulator (320–440 nm) for 5 min.  
The irradiated samples were dried and electrophoresed in a 20% denaturing 
polyacrylamide gel.  The gel was then exposed to a phosphor screen, and the relative 
amounts of DNA in each band were quantitated by phosphorimagery (ImageQuant).  
3.2.5 Binding Constant Determination 
The fraction of DNA cleaved in each lane on the gel was normalized and plotted against 
the log of the concentration of rhodium complex.  At least three photocleavage titrations 
were carried out for each metal complex.  The pooled data were fit to a sigmoidal curve 
using OriginPro 6.1.  The resulting midpoint value (i.e., the log of [rhodium complex] at 
the inflection point of the curve) was converted to units of concentration ([Rh50%]).  The 
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dissociation constant was calculated according to Kd = [Rh50%] − 0.5[DNA], and the 
binding constant was defined as KB = 1/Kd.  The errors were derived from the errors 
associated with the midpoint values.  For complexes that did not photocleave DNA, a 
binding competition titration was carried out with a constant amount (1 µM) of 
Rh(bpy)2(chrysi)3+ added to each sample.  The binding and dissociation constants of the 
non-photocleaving complex were calculated by solving simultaneous equilibria involving 
DNA, Rh(bpy)2(chrysi)3+ and the complex in question in Mathematica 6.0. 
3.2.6 Cell Culture 
HCT116N and HCT116O cells were grown in RPMI medium 1640 supplemented with: 
10% FBS; 2 mM L-glutamine; 0.1 mM non-essential amino acids; 1 mM sodium 
pyruvate; 100 units/mL penicillin; 100 µg/mL streptomycin; and 400 µg/mL geneticin 
(G418).  Cells were grown in tissue culture flasks and dishes (Corning Costar, Acton, 
MA) at 37°C under 5% CO2 atmosphere. 
3.2.7 Cellular Proliferation ELISA 
HCT116N and HCT116O cells were plated in 96-well plates at 2,000 cells/well and 
allowed 24 hours to adhere.  The cells were then incubated with rhodium complexes for 
the durations specified.  For incubation less than 72 hours, the Rh-containing media was 
replaced with fresh media, and the cells were grown for the remainder of the 72 hour 
period.  Cells were labeled with BrdU 24 hours before analysis.  The BrdU incorporation 
was quantified by antibody assay according to established procedures.34,35  Cellular 
proliferation was expressed as the ratio of the amount of BrdU incorporated by the treated 
cells to that of the untreated cells. 
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3.3. Results 
3.3.1 Binding Affinities for Metal Complexes at Single Base Mismatches 
The binding constants of the family of Rh(L2)chrysi3+ complexes at a CC and AC 
mismatch in a 29-mer DNA hairpin with the sequence: 
5ʹ′- GGCAGGXATGGCTTTTTGCCATCCCTGCC-3ʹ′ 
(X = C or A, underline denotes the mismatch) were measured.  The hairpin sequence 
allows cleavage site determination on both strands around the DNA mismatch.  By 
irradiating samples of DNA titrated with varying concentrations of a rhodium complex, a 
photocleavage titration curve is obtained from which the binding constant of the rhodium 
complex is determined.  A typical autoradiogram, taken after electrophoresis through a 
denaturing gel, of samples in a photocleavage titration with rac-Rh(bpy)2chrysi3+ at a CC 
mismatch is shown in figure 3.4 (A).  The position of the photocleavage bands indicates 
that Rh(bpy)2chrysi3+ cleaves one base neighboring the mismatch site near the 3’-end.  
This cleavage pattern is found both for rac-Rh(phen)2chrysi3+ and rac-Rh(DIP)2chrysi3+ 
and holds for the AC mismatch for rac-Rh(bpy)2chrysi3+ and rac-Rh(phen)2chrysi3+.  No 
other photocleavage bands are observed, demonstrating the high specificity of 
Rh(L2)chrysi3+ complexes binding to the mismatch.  The photocleavage titration curve is 
generated from the autoradiogram by quantifying the amount of photocleavage relative to 
the total amount of DNA at each Rh concentration.  Pooled data from at least three 
repeats were fitted to a sigmoidal curve (Figure 3.4, B) for determination of the midpoint 
([Rh50%]) and the dissociation constant (Kd). The Kd value for rac-Rh(bpy)2chrysi3+ at a 
CC mismatch is found to be 30 nM.  For rac-Rh(phen)2chrysi3+ and rac-Rh(DIP)2chrysi3+ 
at a CC mismatch, Kd values of 320 nM and 11 µM are found, respectively (Table 3.1). 
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Figure 3.4. Binding affinities determined through DNA photocleavage.  The DNA 
hairpin sequence is 5’-GGCAGGXATGGCTTTTTGCCATCCCTGCC-3’ (X = C or A, 
underline denotes the mismatch). Samples were irradiated and electrophoresced through a 
20% denaturing PAGE gel. A light control (LC, without rhodium) and dark control (DC, 
without irradiation) were included. A representative autoradiogram of a photocleavage 
titration with Rh(bpy)2chrysi3+ (A, arrows indicate positions of mismatched bases) and a 
representative sigmoidal curve fit of pooled data from photocleavage titrations for 
binding constant determination (B) are shown.   
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For the AC mismatch with both rac-Rh(bpy)2chrysi3+ and rac-Rh(phen)2chrysi3+, Kd 
values are somewhat higher, as we expect given the greater thermodynamic stability of an 
AC mismatch versus a CC mismatch. Rac-Rh(DIP)2chrysi3+ does not yield any 
photocleavage up to 100 µM; thus, its Kd value is estimated to be greater than that.  
 As with phenanthrenequinone diimine rhodium complexes containing saturated 
amine ligands, Rh(NH3)4 chrysi3+ and rac-Rh(HDPA)2chrysi3+ promote relatively little 
DNA cleavage upon irradiation.36 As a result, their binding affinities were determined 
through binding competition titrations with 1 µM rac-Rh(bpy)2chrysi3+. Based on the 
binding constant of Rh(bpy)2chrysi3+, the binding constant of Rh(NH3)4chrysi3+ is 
calculated by solving simultaneous equilibria at the inflection point of the photocleavage 
titration curve.  Through this competitive titration, the binding constant of 
Rh(NH3)4chrysi3+ at a CC mismatch is found to be 1.0 × 108 M−1.  At an AC mismatch, 
KB of Rh(NH3)4chrysi3+ is 3.4 × 106 M−1. From similar binding competition titrations, the 
binding constant of rac-Rh(HDPA)2chrysi3+ is found to be 2.0 × 107 M−1 at a CC 
mismatch and 2.6 × 106 M−1 at an AC mismatch.  It is apparent that the binding affinity 
correlates inversely with complex size; the smallest complex, Rh(NH3)4chrysi3+, shows 
the highest affinities for mismatched sites.  The binding constants for the entire series of 
Rh(L2)chrysi3+ complexes are summarized in table 3.1. 
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Table 3.1.  Binding Affinities of Rh(L)2chrysi3+ complexesc for CC and AC 
Mismatches. Binding constants are determined from photocleavage or binding 
competition titrations using a DNA hairpin with the sequence: 
5’- GGCAGGXATGGCTTTTTGCCATCCCTGCC-3’ 
X = C or A, underline denotes the mismatch. Samples were irradiated with a solar 
simulator (320–440 nm) at 37°C in 50 mM NaCl, 10 mM NaPi, pH 7.1 as described in 
the Experimental section. For the polypyridyl complexes, values are given for racemic 
mixtures. Uncertainties are estimated to be 10%. 
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3.3.2 Inhibition of Cellular Proliferation by ELISA Assay 
An ELISA assay for DNA synthesis was used to quantify the effects of the 
metalloinsertors on the proliferation of HCT116N cells (MMR-proficient) and HCT116O 
cells (MMR-deficient).26  Both cell lines were incubated with 0–25 µM of each member 
of the Rh(L)2chrysi3+ family except Rh(DIP)2chrysi3+, which was administered at 0–5 µM 
concentrations due to its unique uptake characteristics.  Incubations were performed for 
12, 24, 48 or 72 hours.  After the 12, 24, and 48 hour incubations, the media containing 
Rh was replaced with fresh media, and the cells were grown for the remainder of the 72 
hour period.  The extent of cellular proliferation is expressed as the ratio of BrdU 
incorporated by the rhodium treated cells as compared to untreated controls.  Figures 3.5–
3.9 show representative data for each member of the Rh(L)2chrysi3+ family at various 
incubation times.  No significant preferential inhibition of the HCT116O cell line is seen 
at incubation times less than 24 hours, consistent with previous results for 
Rh(bpy)2chrysi3+, with the exception of Rh(DIP)2chrysi3+, which displays a small 
differential effect at 12 hours.26  With longer incubation times, however, 
Rh(NH3)4chrysi3+ in particular (figure 3.9) displays a strong differential effect with 
preferential inhibition of the MMR-deficient HCT116O cell line over the MMR-
proficient HCT116N cell line.  In particular, 48 hour treatment with 10 µM 
Rh(NH3)4chrysi3+ inhibits the proliferation of the HCT116O line by 82±2% while 
exerting little to no effect on the HCT116N line (7±6% inhibition). 
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Figure 3.5. Inhibitory effects of Rh(DIP)2chrysi3+ as a function of incubation time on 
cellular proliferation.  Shown are plots of BrdU incorporation normalized to the BrdU 
incorporation of untreated cells as a function of rhodium concentration. Standard error 
bars for 5 trials are shown.  MMR-proficient HCT116N cells (green) and MMR-deficient 
HCT116O cells (red) were plated and allowed 24 hours to adhere before incubation with 
0–5 µM Rh(DIP)2chrysi3+ for 12, 24, or 48 hours.  At the end of the incubation, the media 
containing Rh was replaced with fresh media and cells were grown for an additional 60 
hours before ELISA analysis.  BrdU was added to the media 24 hours prior to analysis.   
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Figure 3.6. Inhibitory effects of Rh(phen)2chrysi3+ as a function of incubation time 
on cellular proliferation.  Shown are plots of BrdU incorporation (a measure of DNA 
synthesis and therefore cellular proliferation) normalized to the BrdU incorporation of 
untreated cells as a function of rhodium concentration.  Standard error bars for 5 trials are 
shown.  MMR-proficient HCT116N cells (green) and MMR-deficient HCT116O cells 
(red) were plated and allowed 24 hours to adhere before incubation with 0–25 µM 
Rh(phen)2chrysi3+ for 12, 24, 48, or 72 hours.  At the end of the 12, 24, and 48 hour 
incubations, the media containing Rh was replaced with fresh media for the remainder of 
the 72 hours, followed by ELISA analysis.  BrdU was added to the media 24 hours prior 
to analysis.   
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Figure 3.7. Inhibitory effects of Rh(bpy)2chrysi3+ as a function of incubation time on 
cellular proliferation.  Shown are plots of BrdU incorporation (a measure of DNA 
synthesis and therefore cellular proliferation) normalized to the BrdU incorporation of 
untreated cells as a function of rhodium concentration.  Standard error bars for 5 trials are 
shown.  MMR-proficient HCT116N cells (green) and MMR-deficient HCT116O cells 
(red) were plated and allowed 24 hours to adhere before incubation with 0–25 µM 
Rh(bpy)2chrysi3+ for 12, 24, 48, or 72 hours.  At the end of the 12, 24, and 48 hour 
incubations, the media containing Rh was replaced with fresh media for the remainder of 
the 72 hours, followed by ELISA analysis.  BrdU was added to the media 24 hours prior 
to analysis.   
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Figure 3.8. Inhibitory effects of Rh(HDPA)2chrysi3+ as a function of incubation time 
on cellular proliferation.  Shown are plots of BrdU incorporation (a measure of DNA 
synthesis and therefore cellular proliferation) normalized to the BrdU incorporation of 
untreated cells as a function of rhodium concentration.  Standard error bars for 5 trials are 
shown.  MMR-proficient HCT116N cells (green) and MMR-deficient HCT116O cells 
(red) were plated and allowed 24 hours to adhere before incubation with 0–25 µM 
Rh(HDPA)2chrysi3+ for 12, 24, 48, or 72 hours.  At the end of the 12, 24, and 48 hour 
incubations, the media containing Rh was replaced with fresh media for the remainder of 
the 72 hours, followed by ELISA analysis.  BrdU was added to the media 24 hours prior 
to analysis.   
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Figure 3.9. Inhibitory effects of Rh(NH3)4chrysi3+ as a function of incubation time on 
cellular proliferation.  Shown are plots of BrdU incorporation (a measure of DNA 
synthesis and therefore cellular proliferation) normalized to the BrdU incorporation of 
untreated cells as a function of rhodium concentration.  Standard error bars for 5 trials are 
shown.  MMR-proficient HCT116N cells (green) and MMR-deficient HCT116O cells 
(red) were plated and allowed 24 hours to adhere before incubation with 0–25 µM 
Rh(NH3)4chrysi3+ for 12, 24, 48, or 72 hours.  At the end of the 12, 24, and 48 hour 
incubations, the media containing Rh was replaced with fresh media for the remainder of 
the 72 hours, followed by ELISA analysis.  BrdU was added to the media 24 hours prior 
to analysis.   
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Figure 3.10 shows the ELISA results for members of the metalloinsertor family as 
a function of incubation time.  We have shown previously that the Λ-enantiomer of 
Rh(bpy)2chrysi3+ is biologically inactive26 and that structurally binding to a mismatch site 
is enantiospecific for the Δ-isomer.23  For this reason, treatment with the 10 µM achiral 
tetraammine complex was compared to treatment with 20 µM racemic mixtures of the 
Rh(L)2chrysi3+ complexes (L = HDPA, bpy, or phen).  The differential effect of rhodium 
treatment between the cells lines was quantified by subtracting the normalized 
percentages of cellular proliferation for each cell line. Notably, the optimal incubation 
time for each compound is inversely related to the hydrophobicity of the ancillary 
ligands, with rac-Rh(phen)2chrysi3+ exhibiting an optimal incubation time of 24 hours. 
This trend also continues with rac-Rh(DIP)2chrysi3+, which exhibits differential effects in 
as little as 12 hours at concentrations as low as 2 µM (Figure 3.5).  Based on the early 
effect at 12 hours, the HDPA complex may have different uptake characteristics (see 
Chapter 4).  With the exception of the HDPA complex, this variation in activity with 
incubation time for the family of complexes parallels closely results seen earlier for 
uptake in HeLa cells by Ru(bpy)2dppz2+, Ru(phen)2dppz2+, and Ru(DIP)2dppz2+ where 
the most rapid uptake is apparent with the lipophilic DIP complex.28, 29 
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Figure 3.10. Inhibitory effects of rhodium metalloinsertors as a function of 
incubation time. Shown are plots of BrdU incorporation normalized to the BrdU 
incorporation of untreated cells as a function of rhodium concentration.  The inhibition 
differential is the difference of the normalized percentages of cellular proliferation for 
each cell line, with standard error bars (SN-O=√(sN2+sO2)).  Cells were incubated with no 
rhodium, 2 µM Rh(DIP)2chrysi3+, 10 µM Rh(NH3)4chrysi3+, or 20 µM Rh(L)2chrysi3+ (L 
= HDPA, bpy, or phen).   
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Figure 3.11 summarizes the differential effects on cell proliferation and the incubation 
time for the family of complexes.  Clear correlations are evident with the binding 
constants for these complexes (Table 3.1).  Significantly, the differential effect in 
inhibiting cell proliferation in MMR-deficient cells is directly correlated to the binding 
affinity of the compound for DNA mismatches.  Rh(NH3)4chrysi3+ (Kb = 1 x 108 M-1 at a 
CC mismatch), for example, shows the largest differential effect in inhibiting 
proliferation of MMR-deficient versus -proficient HCT116 cells after 72 hours (79±5%), 
while Rh(phen)2chrysi3+ (Kb = 3.2 x 106 M-1 at a CC mismatch) shows a small differential 
effect (17±7%).  The DIP complex is rapidly taken up by the cells but also shows only a 
small differential inhibitory effect correlating with its poor specific binding at the 
mismatch site. 
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Figure 3.11. Inhibitory effects of rhodium metalloinsertors as a function of metal 
complex identity. Shown are bar graphs of BrdU incorporation normalized to the BrdU 
incorporation of untreated cells as a function of rhodium concentration.  The inhibition 
differential is the difference of the normalized percentages of cellular proliferation for the 
two cell lines, HCT116O versus HCT116N.  Cells were incubated with no rhodium, 2 
µM Rh(DIP)2chrysi3+, 10 µM Rh(NH3)4chrysi3+, or 20 µM Rh(L)2chrysi3+ (L = HDPA, 
bpy, or phen).  A correlation between mismatch binding affinity and differential 
inhibition of MMR-deficient cells is evident. 
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3.4. Discussion 
A clear trend emerges when comparing the binding constants of the series of rhodium 
complexes to mismatched sites: The DNA mismatch binding affinity increases as the size 
of the ancillary ligand decreases.  This trend is consistent with what we have learned 
from the structural studies, specifically that mismatch binding by insertion via the minor 
groove is subject to stringent space constraints.  With major groove intercalation, the base 
rise is increased and the major groove offers space to accomodate the ancillary ligands.  
In contrast, with insertion, there is no increase in base pair rise, the mismatched bases are 
instead ejected and replaced by the deeply inserted chrysi ligand.  Moreover, the minor 
groove, small even for hydrophobic groove binding molecules, offers little space for the 
ancillary ligands.  While little enantioselectivity is apparent for intercalation of bpy 
complexes into B-form DNA, Δ-Rh(bpy)2chrysi3+  binds enantiospecifically to single 
base mismatches.23,37  Thus steric interactions of the ancillary ligands are seen as an 
extremely important factor governing the binding affinity of a metal complex at the 
mismatch site.   
 The other clear trend is that binding to the CC mismatch is tighter than binding to 
the AC mismatch. We understand this trend since AC is the thermodynamically more 
stable mismatch, and in this case is estimated to stabilize the hairpin duplex by ~0.5 
kcal/mol relative to one containing a CC mismatch.38 This stabilization is translated into a 
higher dissociation constant (smaller binding constant) for the entire series of rhodium 
complexes.  This decrease in binding affinity depends upon the greater energy required to 
eject the mismatched bases from the base pair stack, as evident crystallographically.23  
Nonetheless, the inverse relationship between the size of the ancillary ligand and the 
binding affinity still holds, with the smallest complex Rh(NH3)4chrysi3+ showing the 
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highest affinity and that of the largest complex Rh(DIP)2chrysi3+ more than two orders of 
magnitude lower. 
Figure 3.12 compares the crystal structure of Δ-Rh(bpy)2chrysi3+ bound to the 
mismatch site23 with models of Δ-Rh(DIP)2chrysi3+ and Rh(NH3)4chrysi3+ similarly 
bound via the minor groove through metalloinsertion.  Preserving the DNA conformation 
from the crystal structure, we see that Δ-Rh(DIP)2chrysi3+ runs into substantial steric 
hindrance as its axial phenyl rings extend up and down into the groove, directly clashing 
with the bases.  However, its equatorial phenyl rings do not pose any steric problems as 
they point away from the DNA.  These observations are supported by the small binding 
constant measured for Rh(DIP)2chrysi3+. Rh(phen)2chrysi3+, intermediate in size, shows 
binding affinities for the mismatches that are an order of magnitude lower than the bpy 
derivative but more than an order of magnitude higher than the DIP complex.  
Rh(HDPA)2chrysi3+ is slightly larger in size than the bpy derivative, but the HDPA 
ligands are more flexible, and there is an opportunity for hydrogen bonding; as a result 
Rh(bpy)2chrysi3+ and Rh(HDPA)2chrysi3+ have comparable affinities for the mismatch. 
Analogously, the large binding constant of Rh(NH3)4chrysi3+ can be mostly attributed to 
its small size.  Here it is reasonable to suggest that the axial ammines may also hydrogen 
bond with the neighboring base pairs to form additional stabilizing interactions.   
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Figure 3.12. Crystal and model structures of rhodium metalloinsertors bound to the 
mismatch site.  Rhodium insertors (red) are shown bound to the DNA (gray) from the 
minor groove, at the mismatch site with the bases (adenine in blue, cytosine in yellow) 
ejected and the chrysi ligand stacked fully with the adjacent base pairs.  The crystal 
structure of Rh(bpy)2chrysi3+ bound to the CA mismatch is shown in (A), along with 
structural models of Rh(DIP)2chrysi3+ (B) and Rh(NH3)4chrysi3+ (C) binding based on the 
crystal structure.  Superposition of the DIP complex upon the rhodium center of the bpy 
complex leads to steric clashes with the sugar-phosphate backbone (possible atoms 
involved in green), whereas the tetraaammine complex is easily accommodated.   
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Nonetheless, as evident in Figure 3.12, the small cone size of the tetraammine structure 
clearly facilitates deep insertion within the minor groove site. In fact, the clear inverse 
correlation of binding affinity with ancillary ligand size, and the finding that 
Rh(DIP)2chrysi3+, despite its cumbersome size, is able to bind at all to a mismatch site 
with some specificity, corroborate our understanding of the driving force and the 
dynamics of mismatch recognition: The π-stacking between the inserted chrysi ligand 
and the adjacent bases provides the major stabilizing force for binding, and both the 
metal complex and DNA distort their conformations to accommodate each other in the 
bound state.  
Importantly, the DNA mismatch binding affinities of the Rh(L)2chrysi3+ family 
correlate well with the differential biological effects seen between the repair-proficient 
HCT116N and repair-deficient HCT116O cell lines (figure 3.13).  This correlation 
supports the hypothesis that DNA mismatches are the target of rhodium metalloinsertors 
in vivo.  Because of this correlation, we may attribute the preferential inhibitory effect on 
MMR-deficient cells to binding of the complexes to DNA mismatches.  Since the MMR-
deficient cells contain more mismatches, the tighter binding complexes would be 
expected to display a greater inhibitory effect.  It should be noted that finding any 
inhibitory effect with these complexes was at first surprising, since they bind DNA non-
covalently and might be expected to be readily displaced. Although the mechanism of 
inhibition is not yet fully understood, it is likely that protein recognition of the metal-
mismatch complex, perhaps by RNA polymerase or topoisomerase, may generate a 
covalent protein/DNA lesion and contribute to the cellular response.  
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Figure 3.13. Inhibitory effects of rhodium metalloinsertors correlate with binding 
affinity for DNA mismatches. Shown are bar graphs of BrdU incorporation normalized 
to the BrdU incorporation of untreated cells as a function of rhodium concentration.  The 
inhibition differential is the difference of the normalized percentages of cellular 
proliferation for the two cell lines, HCT116O versus HCT116N.  Cells were incubated 
with no rhodium, 2 µM Rh(DIP)2chrysi3+, 10 µM Rh(NH3)4chrysi3+, or 20 µM 
Rh(L)2chrysi3+ (L = HDPA, bpy, or phen).  A correlation between mismatch binding 
affinity and differential inhibition of MMR-deficient cells is evident. 
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The differential inhibitory effect seen with Rh(HDPA)2chrysi3+ cannot be 
understood simply on the basis of binding affinities. Despite having essentially the same 
mismatch binding affinity as Rh(bpy)2chrysi3+, the HDPA complex preferentially inhibits 
the MMR-deficient cell line almost as well as Rh(NH3)4chrysi3+ with long incubation 
times; with short times of incubation, the differential inhibitory effect by 
Rh(HDPA)2chrysi3+ is greatest.  Both the HDPA ligand and the primary amine group 
have the potential to form hydrogen bonds.  This hydrogen bonding capability and 
flexibility of the ligands might serve to make them more effective inhibitors of any 
protein-DNA interactions.  Indeed, ruthenium complexes bearing HDPA ligands have 
been shown to exhibit DNA binding and cytotoxicity.39 
Certainly, as with any pharmaceutical design, cellular uptake must also be 
considered.  In the case of the HDPA complex, based upon the variations in inhibitory 
effect with incubation time, the amine ligands may facilitate nuclear uptake.  Dppz 
analogues with the HDPA ligands have not yet been examined with respect to their 
uptake characteristics.  For the bpy complexes, the 48 hour incubation time required for 
Rh(bpy)2chrysi3+ to exert its anti-proliferative effect matches the 48 hour requirement 
observed for Ru(bpy)2dppz2+ uptake in HeLa cells.25,27  The more lipophilic 
Rh(DIP)2chrysi3+ here is found to exert anti-proliferative effects at much shorter 
incubation times and lower concentrations, which also matches the accelerated uptake 
observed for Ru(DIP)2dppz2+.  Cellular uptake is surely a rate-limiting factor in 
biological activity of the rhodium metalloinsertors.  Yet cellular uptake is not the only 
challenge; proper subcellular localization must also be achieved in order for any drug to 
act upon its target.  It has been well established that lipophilic cations preferentially target 
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the mitochondria, whereas hydrophilic cations do not.40,41  It may be that 
Rh(HDPA)2chrysi3+ and Rh(NH3)4chrysi3+ lack the lipophilicity required for 
mitochondrial accumulation, allowing a greater proportion of these compounds to reach 
the nucleus once inside the cell.  This difference in intracellular partitioning could then 
account for the differential effects of Rh(HDPA)2chrysi3+. 
3.5. Conclusions 
In the development of octahedral rhodium complexes as anti-cancer agents, the choice of 
ancillary ligand can be seen as a design tradeoff, with the binding affinity for a DNA 
mismatch greatly outweighing uptake properties as the critical factor in the successful 
targeting of repair-deficient cells.  Beyond their effects on DNA binding and overall 
cellular uptake, it is highly likely that the ancillary ligands affect the cellular response in 
other ways, including the potential for hydrogen bonding and differences in uptake and 
intracellular distribution.  Here we are confronted with a tradeoff that may seem 
inevitable: more hydrophobic ligands facilitate cellular uptake but impede mismatch 
binding. Perhaps this trade-off can be avoided by making conjugates arranged with 
functional moieties tethered with consideration of the structure of the DNA-bound 
complex associated snugly in the minor groove.  Most importantly, these data support the 
contention that the cell-specific inhibitory effect we observe depends upon binding to the 
DNA mismatch inside the cell.   This cell-specific strategy thus represents a promising 
direction in the development of small metal complexes that react preferentially in MMR-
deficient cells, those susceptible to cancerous transformation. 
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Chapter 4: Cytotoxic effects of Rh metalloinsertors 
with dipyridylamine ancillary ligands 
 
4.1. Introduction 
The direct correlation between the binding affinity of rhodium metalloinsertors for DNA 
mismatches and the differential in their activity between the HCT116N and HCT116O 
cell lines fails to predict the high activity of [Rh(HDPA)2chrysi]3+.  In light of the shorter 
incubations required for this complex, it seems likely that accelerated cellular uptake is a 
contributing factor in the increased cellular response.  As [Rh(HDPA)2chrysi]3+ is not 
luminescent, another method is needed to examine its cellular uptake.  The high atomic 
mass and monoisotopic distribution of rhodium make the cellular accumulation of 
rhodium metalloinsertors well suited to analysis by inductively coupled plasma–mass 
spectrometry (ICPMS).1-3 The high anti-proliferative activity of [Rh(HDPA)2chrysi]3+ 
also raised questions as to whether additional biological responses to rhodium treatment 
might appear that were not observed with other complexes. 
The preceding work demonstrated the anti-proliferative activity of rhodium 
metalloinsertors against human cancer cell lines as a function of mismatch repair 
competency, with a mismatch repair deficient cell line displaying enhanced susceptibility 
to the agents versus a repair proficient sister cell line.  Importantly, the difference in 
activity observed between the cell lines was positively correlated with the binding affinity 
for DNA mismatches, supporting the hypothesis that mismatches are the cellular target of 
rhodium metalloinsertors. In these studies activity was measured with an ELISA for 
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DNA synthesis, which served as a proxy for cellular proliferation.  This assay however 
does not distinguish between senescence and other types of cell death, and therefore is 
insufficient to demonstrate cytotoxicity.  Here, the MTT assay for metabolic activity is 
used as a true measure of cytotoxicity, and rhodium metalloinsertors are shown to 
preferentially kill the MMR-deficient HCT116O cell line versus its MMR-proficient 
sister cell line, HCT116N.  Caspase inhibition and dye exclusion assays are used to show 
that this cell death occurs through a necrotic rather than apoptotic mechanism.  
Furthermore, propidium iodide staining and flow cytometric analysis are used to show 
that cell death is preceded by cell cycle arrest at the G1/S phase boundary.  This 
observation is consistent with activation of the DNA damage response by rhodium 
metalloinsertors. 
4.2. Experimental Protocols 
4.2.1 Materials 
RhCl3 was purchased from Pressure Chemical, Inc. (Pittsburgh, PA).  [Rh(NH3)5Cl]Cl2 
was obtained from Strem Chemical, Inc. (Newburyport, MA).  2,2'-dipyridylamine 
(HDPA) and Sephadex ion exchange resin were obtained from Sigma Aldrich (St. Louis, 
MO).  Sep-Pak C18 solid phase extraction cartridges were purchased from Waters 
Chemical Co. (Milford, MA). Media and supplements were purchased from Invitrogen 
(Carlsbad, CA). The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
(MTT) labeling reagant and acidified lysis buffer (10% SDS in 10 mM HCl) were 
purchased in kit format from Roche Molecular Biochemicals (Mannheim, Germany).  Z-
VAD-FMK caspase inhibitor was purchased from Promega.  The PARP inhibitor 3,4-
dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) was purchased from 
Sigma Aldrich.  All commercial materials were used as received.   
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Figure 4.1. Rhodium metalloinsertors bearing dipyridylamine ancillary ligands. 
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4.2.2 Synthesis of MeDPA Ligand 
N-methyl-2,2'-dipyridylamine (MeDPA). An oven-dried 50 mL round bottom flask 
equipped with a stirbar and septa was charged with sodium hydride (0.24 g, 10 mmol) 
and anhydrous THF under a constant purge of argon.  The suspension was cooled in an 
ice bath. 2,2'-dipyridylamine (1.71 mg, 10 mmol) in 2 mL anhydrous THF was added 
dropwise at 0 °C to the hydride suspension. Iodomethane (1.85 g, 13 mmol) was added 
dropwise as the reaction warmed slowly to room temperature and brought to a reflux for 
17 hours. The reaction was concentrated in vacuo and extracted with dichloromethane 
and dilute sodium bicarbonate.  The organic layer was dried over sodium sulfate and 
concentrated to a light yellow oil. The desired product can be purified by silica gel 
chromatography with 1:9 ethyl acetate:hexane mobile phase. Yield: 0.47 g (2.5 mmol, 
25 %) 1H-NMR (CDCl3): 8.35 (d of d, 2H); 7.54 (t, 2H); 7.17 (d, 2H); 6.86 (t, 2H), 3.62 
(s, 3H). ESI-MS: 186 m/z [M+H]+ (observed). 
4.2.3 Synthesis of Metal Complexes 
[Rh(HDPA)2chrysi]Cl3 was prepared according to previously described procedures 
(Chapter 3). [Rh(MeDPA)2chrysi]Cl3 was synthesized by refluxing 
[Rh(NH3)4chrysi]TFA3 with 2 equivalents of MeDPA in 1:1 ethanol:water overnight 
(figure 4.2.).  The reaction mixture was cooled to room temperature, and the solvent was 
removed in vacuo.  The desired product was isolated by cation exchange chromatography 
with Sephadex CM-25 resin, eluting with 0.03 M MgCl2 (aq).  Excess magnesium was 
removed by solid phase extraction with a Sep-pak C18 cartridge and the TFA counterion 
was exchanged for the chloride by anion exchange chromatography with Sephadex QAE-
125 resin. 
  
 77 
 
 
 
 
 
 
 
Figure 4.2. Synthesis of [Rh(MeDPA)2chrysi]Cl3. 
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Formation of the desired product was confirmed by UV/vis (H2O, pH 5): 295 nm (55,000 
M-1cm-1), 320 nm (39,700 M-1cm-1), 390 nm (14,000 M-1cm-1) and ESI-MS (cation): 
727.1 m/z ([M-2H]+), 364.3 m/z ([M-H]2+) obs., 727.2 m/z ([M-2H]+) calc.  Purity was 
confirmed by analytical HPLC (tretention = 13.5 minutes, 10:90:0.1 MeCN:H2O:TFA to 
40:60:0.1 MeCN:H2O:TFA over 45 minutes). 
4.2.4 Inductively-Coupled Plasma Mass Spectrometry (ICP-MS) 
Analysis of exogenous transition metal complexes by ICP-MS is greatly enabled by the 
fact that no background exists within the cell. While ICP-MS and AAS represent very 
sensitive methods to assay for metal content, these assays cannot be accomplished with 
monitoring in real time. Cell lysates are instead prepared from cells that have been 
incubated with metal complex, prior to assay for metal uptake. When adherent cells are 
used, they are either detached from the culture dish and then lysed, or lysed directly in the 
dish. Alternatively, the cells can be detached and treated with complex in suspension. 
This cell lysate is analytically diluted, and the amount of metal in the solution is 
quantified. Rhodium counts measured in the samples are a highly linear measure of 
concentration, as shown by the calibration standard shown in figure 4.4.  The normalized 
counts from the samples are shown with standard error bars for three trials.  
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Figure 4.3. Cellular ICP-MS. Methodology for analysis of rhodium accumulation and 
localization in HCT116 cell lines by ICP-MS.  After incubation with rhodium complexes, 
cells are counted and separated into three samples.  Cell lysates, nuclear fractions, and 
mitochondrial fractions are then prepared and analyzed for rhodium content by ICP-MS. 
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Figure 4.4. ICP-MS Calibration. Regression fit for rhodium counts as a function of 
concentration for serial dilutions of a rhodium standard solution.  Rhodium counts are a 
linear function of concentration. 
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4.2.5 Cell Culture 
HCT116N and HCT116O cells were grown in RPMI medium 1640 supplemented with: 
10% FBS; 2 mM L-glutamine; 0.1 mM non-essential amino acids; 1 mM sodium 
pyruvate; 100 units/mL penicillin; 100 µg/mL streptomycin; and 400 µg/mL geneticin 
(G418).  Cells were grown in tissue culture flasks and dishes (Corning Costar, Acton, 
MA) at 37°C under 5% CO2 and humidified atmosphere. 
4.2.6 Preparation of whole cell lysate 
The whole cell pellet was resuspended in 1% HNO3 (v/v), lysed by repeated freeze/thaw 
cycles in liquid nitrogen, and analyzed for rhodium content on an HP-4500 ICP-MS unit. 
4.2.7 Preparation of nuclei 
The cell pellet was suspended in extraction buffer (320 mM sucrose, 5 mM MgCl2, 10 
mM HEPES, 1% Triton X-100, pH 7.4), briefly vortexed, and incubated on ice for 10 
minutes.  The nuclei were collected by centrifugation at 2000 x g for 3-4 minutes.  The 
pellet was rinsed with wash buffer (320 mM sucrose, 5 mM MgCl2, 10 mM HEPES) 
twice.  Nuclei were then counted with 1:1 dilution in Trypan blue (0.4% in PBS) and 
resuspended in 1% HNO3 (v/v), homogenized by three freeze/thaw cycles in liquid 
nitrogen, and analyzed for rhodium content on an HP-4500 ICP-MS unit. 
4.2.8 Preparation of mitochondrial fraction 
The cell pellet was suspended in extraction buffer (isotonic solution, 10 mM HEPES, pH 
7.5, 200 mM mannitol, 70 mM sucrose, and 1 mM EGTA) and Dounce homogenized or 
lysed with detergent for 5 minutes on ice.  The homogenate or lysate was then 
centrifuged at 600 x g for 5 minutes.  The supernatant was carefully collected and 
transferred to a fresh microcentrifuge tube.  After centrifugation at 11,000 x g, the pellet 
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was collected and resuspended in 1% HNO3 (v/v), homogenized by three freeze/thaw 
cycles in liquid nitrogen, and analyzed for rhodium content on an HP-4500 ICP-MS unit. 
4.2.9 Cellular Proliferation ELISA 
HCT116N and HCT116O cells were plated in 96-well plates at 2,000 cells/well and 
allowed 24 hours to adhere.  The cells were then incubated with rhodium for the 
durations specified.  For incubation less than 72 hours, the Rh-containing media were 
replaced with fresh media, and the cells were grown for the remainder of the 72 hour 
period.  Cells were labeled with BrdU 24 hours before analysis.  The BrdU incorporation 
was quantified by antibody assay according to established procedures.4,5 Cellular 
proliferation was expressed as the ratio of the amount of BrdU incorporated by the treated 
cells to that of the untreated cells. 
4.2.10 MTT Cytotoxicity Assay 
HCT116N and HCT116O cells were plated in 96-well plates at 50,000 cells/well and 
incubated with rhodium for the durations specified.  After rhodium incubation cells were 
labeled with MTT for 4 hours at 37°C under 5% CO2 and humidified atmosphere.  The 
resulting formazan crystals were dissolved with 10% SDS acidified with 10 mM HCl 
purchased from Roche in kit format according to the manufacturer’s instructions.  The 
dissolved formazan was quantified as the absorbance at 570 nm minus the background 
absorbance at 690 nm.  Percent viability was determined as the ratio of the amount of 
formazan in the treated cells to that of the untreated cells.  For caspase inhibition assays, 
Z-VAD-FMK was added from a 20 mM stock solution in DMSO to a final concentration 
of 20–40 µM.  For PARP inhibition assays, DPQ was added from a 5 mg/mL stock in 
DMSO to a final concentration of 25–50 µM. 
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Figure 4.5. MTT cytotoxicity assay.  The tetrazolium salt (MTT) is reductively cleaved 
by various mitochondrial enzymes to yield formazan crystals, leading to an absorbance 
band centered around 570 nm.  The crystals can be dissolved by addition of 10% SDS 
acidified with 10 mM HCl to give a purple solution.  The absorbance of this solution 
directly reflects the number of metabolically viable cells in the sample. 
  
 84 
4.2.11 Cell Cycle Distribution Flow Cytometry Assay 
Cells were harvested from adherent culture by trypsinization and washed with cold PBS.  
The resultant pellet was resuspended in PBS (chilled to 4 °C), and ice-cold ethanol was 
added dropwise to a final concentration of 70% (v/v), with continuous gentle agitation.  
Cells were fixed at 4°C for 30 minutes and stored for up to one week.  Prior to analysis, 
the fixed cells in 70% ethanol were diluted 1:3 in cold PBS and centrifuged at 1,400 x g 
for 5 minutes.  The resultant pellet was washed twice and resuspended in ice-cold PBS.  
Ribonuclease was added to a final concentration of 30 µg/mL and the cells were 
incubated overnight at 4 °C.  The next day propidium iodide was added to a final 
concentration of 20 µg/mL and cells were analyzed by flow cytometry.  Data analysis 
was performed using the FloJo software package (version 8.7.1). 
4.2.12 Cell Death Mode Flow Cytometry Assay 
After 24–72 hour incubation with rhodium, cells were harvested from adherent culture by 
trypsinization and washed with ice cold PBS.  The resultant pellet was resuspended in 
ice-cold PBS and stained with propidium iodide and with YO-PRO-1 to a final 
concentration of 200 nM for 30 minutes on ice prior to analysis by flow cytometry. 
4.3. Results 
4.3.1 ICP-MS for Cellular Accumulation 
Each cell line was treated with 10 µM of [Rh(bpy)2chrysi]3+, [Rh(HDPA)2chrysi]3+, or 
[Rh(NH3)4chrysi]3+ for 48 hours.  After rhodium incubation, the cells were harvested 
from adherent culture by trypsinization, washed with cold PBS, counted on a 
hemacytometer, and separated into three equal groups.  Whole cell lysate was prepared 
from the first group, nuclei were isolated from the second, and a cellular fraction enriched 
in mitochondrial was isolated from the third. 
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The fractions were analyzed for rhodium levels by ICP-MS, and the data are 
shown in figure 4.6.  Two notable observations can be made.  As expected, the HDPA 
complex exhibits a higher degree of cellular uptake than the other complexes.  This 
supports the notion that the early activity displayed by the complex in the ELISA assay 
(Chapter 3) results from accelerated uptake.  It should be noted that these treatment 
conditions directly reflect those used in the ELISA.  Secondly, the ammine complex 
exhibits a higher degree of nuclear localization, as determined by the ratio of nuclear 
counts to whole cell counts.  This is not surprising; since the ammine ligands lack the 
lipophilic nature of the bpy and HDPA ligands, they are not as likely to be concentrated 
in the mitochondria, where lipophilic cations are known to accumulate.6-11 There is also 
no real difference in the rhodium levels in mitochondria between HCT116N and 
HCT116O cells. 
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Figure 4.6. ICP-MS Assay for Rhodium Accumulation. Normalized rhodium counts 
for whole cell lysates (top left), isolated nuclei (top right), along with the ratio of 
mitochondrial counts to whole cell counts (bottom left), and the ratio of nuclear counts to 
whole cell counts (bottom right). Standard error bars for three trials are shown. 
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4.3.2 MTT Cytotoxicity Assay 
The cytotoxicities of [Rh(HDPA)2chrysi]3+ and [Rh(MeDPA)2chrysi]3+ were determined 
by MTT assay.  Briefly, reduction of the MTT reagent by mitochondrial enzymes leads to 
the production of formazan, which can then be dissolved in acidified SDS and produces a 
characteristic absorbance at 570 nm.  This absorbance reflects the relative metabolic 
activity, which in turn reflects the percentage of viable cells in each sample.
 HCT116N and HCT116O cells were plated and treated with 0-25 µM of 
[Rh(HDPA)2chrysi]3+ or [Rh(bpy)2chrysi]3+ for 24, 48, or 72 hours.  The results are 
shown in figure 4.7.  At 24 hours, no differential cytotoxicity is observed for either 
complex, but at 48 to 72 hours [Rh(HDPA)2chrysi]3+ clearly displays an enhanced 
toxicity in the MMR-deficient HCT116O cell line versus the HCT116N cell line.  For 
example, 72 hours after treatment with 20 µM [Rh(HDPA)2chrysi]3+, the number of 
viable HCT116N cells is 80 ± 5.2 % of untreated controls, whereas the number of viable 
HCT116O cells is 37 ± 4.4 % of untreated controls. 
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Figure 4.7. [Rh(HDPA)2chrysi]3+ is selectively toxic in MMR-deficient cells.  
HCT116N and HCT116O cells were plated in 96-well format at densities of 5 x 104 
cells/well and treated with 0–25 µM of [Rh(bpy)2chrysi]3+ or [Rh(HDPA)2chrysi]3+.  
After 24–72 hours, the cells were labeled with MTT for 4 hours.  The resulting formazan 
crystals were dissolved by addition of 10% SDS acidified with 10 mM HCl, and 
absorbance was measured at 570 nm.  While the first generation complex 
[Rh(bpy)2chrysi]3+ is non-toxic, the dipyridylamine derivative [Rh(HDPA)2chrysi]3+ 
exhibits toxicity specifically in the MMR-deficient HCT116O cell line. 
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Before testing  [Rh(MeDPA)2chrysi]3+ in the MTT assay, the complex was tested in the 
ELISA (figure 4.8.)  HCT116N and HCT116O cells were plated and treated with 0-25 
µM of [Rh(MeDPA)2chrysi]3+ for 12–72 hours. The appearance of differential activity 
against the HCT116O cell line after a 12 hour incubation suggested that the MeDPA 
complex showed the same accelerated uptake as [Rh(HDPA)2chrysi]3+.  As expected 
then, [Rh(MeDPA)2chrysi]3+ also shows differential toxicity against the HCT116O cell 
line in the MTT assay comparable to that of [Rh(HDPA)2chrysi]3+ from 0–50 µM over 
48–72 hours (figure 4.9). 
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Figure 4.8. [Rh(MeDPA)2chrysi]3+ selectively inhibits MMR-deficient cells in 
ELISA.  HCT116N and HCT116O cells were plated in 96-well format at densities of 
2?103 cells/well and treated with 0–25 µM of [Rh(MeDPA)2chrysi]3+.  After 12–72 
hours, the media was removed and replaced with fresh media containing no rhodium.  
Cells were labeled with BrdU for 24 hours prior to analysis. 
  
 91 
 
 
 
 
 
Figure 4.9. [Rh(MeDPA)2chrysi]3+ is selectively toxic in MMR-deficient cells.  
HCT116N and HCT116O cells were plated in 96-well format at densities of 5?104 
cells/well and treated with 0–50 µM of [Rh(HDPA)2chrysi]3+ or [Rh(MeDPA)2chrysi]3+.  
After 24–72 hours, the cells were labeled with MTT for 4 hours.  The resulting formazan 
crystals were dissolved by addition of 10% SDS acidified with 10 mM HCl, and 
absorbance was measured at 570 nm. 
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4.3.3 Effects on the Cell Cycle. 
Given the previous observation that the complexes inhibit DNA synthesis, a flow 
cytometry assay was performed to determine if the cytotoxicity of [Rh(HDPA)2chrysi]3+ 
is accompanied by disruption of the cell cycle.  MMR-proficient HCT116N and MMR-
deficient HCT116O cells were treated with 20 µM [Rh(HDPA)2chrysi]3+ for 24 or 48 
hours. After treatment, cells were stained with propidium iodide (PI) and analyzed by 
flow cytometry.  The PI fluorescence reports the amount of DNA in each cell and follows 
a bimodal distribution, where the first peak contains cells with one copy of the genome, 
i.e., cells in G0/G1 phase, and the second peak contains cells with two copies of the 
genome, i.e., cells in G2 or M phase.  Cells in S-phase occupy the region between the two 
peaks.  Figure 4.10 shows these distributions for both cell lines, with or without rhodium 
treatment.  In both cases, a decrease in the area under the curve between the peaks can be 
seen, indicating a depletion of the S-phase populations.  Figure 4.11 fits the raw 
distributions to G1, S, or G2/M phases, and confirms the depletion of the S-phase 
population, concomitant with an increase in the G1 population. Notably, at this 
concentration of [Rh(HDPA)2chrysi]3+ large differentials in both the ELISA and MTT 
assay were observed.  The changes to the cell cycle are more pronounced in the MMR-
deficient HCT116O cell line, which continues to grow aggressively at 48 hours (> 50% 
S-phase) in the absence of rhodium treatment, whereas growth of the HCT116N cell line 
slows slightly as the density of the culture increases.  Furthermore, the HCT116O cell 
line also shows a significant increase in the G2/M population as well as the G1 
population.   
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Figure 4.10. Cell cycle distribution assay.  HCT116N and HCT116O cells were treated 
with 20 µM [Rh(HDPA)2chrysi]3+ for 24 or 48 hours.  After fixation and staining with PI, 
cells were analyzed by flow cytometry. Upon rhodium treatment, the S-phase population 
is depleted, as can be seen by the decreased density of cells between the G1 and G2/M 
peaks of the distribution. 
  
 94 
 
 
 
 
Figure 4.11. Cell cycle distribution assay.  HCT116N (top) and HCT116O (bottom) 
cells were treated with 20 µM [Rh(HDPA)2chrysi]3+ for 24 or 48 hours.  After fixation 
and staining with PI, cells were analyzed by flow cytometry.  The raw distributions were 
analyzed for cell cycle phase using commercially available software.  Upon rhodium 
treatment, the S-phase population is depleted, with a concomitant increase in the G1-
phase population. 
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4.3.4 Cell Death Pathway by Flow Cytometry 
To characterize the cell death occurring in response to rhodium treatment, a dye 
exclusion flow cytometry assay, depicted schematically in figure 4.12, was employed. 
The assay differentiates between live cells, dead cells, and cells undergoing apoptosis or 
necrosis through concurrent staining with propidium iodide (a dead cell permeable dye) 
and YO-PRO-1 (an apoptotic cell permeable dye).  By plotting the fluorescence of the 
YO-PRO-1 channel against the PI channel, a pattern emerges.  Healthy cells are seen in 
the lower lefthand corner of the plot.  Apoptotic cells exhibit higher YO-PRO-1 
fluorescence, but still exclude propidium iodide, placing them in the upper lefthand 
quadrant of the pattern.  Dead cells admit both dyes and are therefore seen in the upper 
righthand quadrant of the image.  Upon flow cytometry analysis, cells can be classified as 
live, apoptotic, necrotic, or dead after gating, or defining regions in the fluorescence 
plane corresponding to each category. 
The HCT116N and HCT116O cell lines were incubated with 0–30 µM of 
[Rh(HDPA)2chrysi]3+ for 24–72 hours.  After harvesting the cells and staining with both 
PI and YO-PRO-1, the cells were analyzed by flow cytometry to obtain raw fluorescence 
data.  Representative data for 20 µM rhodium treatment for 72 hours are shown in figure 
4.13.  YO-PRO-1 fluorescence is shown on the y-axis, and PI fluorescence is shown on 
the x-axis.  The color scale represents the number of cells, with blue indicating fewer 
cells at a given pair of fluorescence levels, and orange representing a greater number of 
cells at a given pair of fluorescence levels.  
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Figure 4.12. Cell death mode dye exclusion assay. HCT116N and HCT116O cells were 
treated with rhodium, harvested, resuspended in PBS, and stained with PI (dead cell 
permeable dye) and YO-PRO1 (apoptotic cell permeable dye).  The cells were gated by 
position in the fluorescence plane and classified as live, apoptotic, necrotic, or dead.  
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Figure 4.13. [Rh(HDPA)2chrysi]3+ induces necrosis in HCT116O cells. HCT116N and 
HCT116O cells were treated with 20 µM [Rh(HDPA)2chrysi]3+ for 72 hours.  Cells were 
harvested, resuspended in PBS, and stained with PI (dead cell permeable) and YO-PRO1 
(apoptotic cell permeable).  The cells were gated by regions in the fluorescence plane and 
classified as live, apoptotic, necrotic, or dead.  Rhodium treatment causes cells to move 
away from the origin, along the necrotic pathway (lower branch of pattern).  The effect is 
more pronounced in the HCT116O cell line. 
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Raw fluorescence data was analyzed by gating the fluorescence events into one of 
four categories, depending on the fluorescence levels of the two dyes.  Figure 4.14 shows 
the resulting histograms of live, apoptotic, necrotic, and dead cells for HCT116N and 
HCT116O cells treated with 0–30 µM [Rh(HDPA)2chrysi]3+ for 72 hours.  The 
percentage of cells in the live region decreases, while the percentages of cells in the 
necrotic and dead regions increase in a concentration-dependent fashion.  The effect is 
more pronounced in the MMR-deficient HCT116O cell line, which drops from 77 ± 7.4 
% to 27 ± 4.8 % of cells in the live region versus the MMR-proficient HCT116N cell 
line, which shows a smaller drop from 59 ± 4.4 % to 30 ± 0.8 % after treatment with 30 
µM [Rh(HDPA)2chrysi]3+. 
Figure 4.15 shows histograms of live, apoptotic, necrotic, and dead cells for 
HCT116N and HCT116O cells treated with 20 or 25 µM [Rh(HDPA)2chrysi]3+ for 24 – 
72 hours.  As before, rhodium treatment induces necrosis preferentially in the MMR-
deficient HCT116O cell line; here the toxicity increases steadily with time.  A slight, but 
appreciable toxicity is seen at 24 hours, and the largest increase in the percentage of 
necrotic and dead cells is seen to occur between 24 and 48 hours after treatment. After 72 
hours, the highest percentages of necrotic and dead cells are seen.  Again, the HCT116O 
cell line, where live cells drop from 73 ± 2.2 %  to 37 ± 2.5 %, is more sensitive to 
rhodium than the HCT116N cell line, where live cells drop from from 58 ± 5.2 % to 47 ± 
5.5 % after treatment with 20 µM [Rh(HDPA)2chrysi]3+ for 72 hours. 
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Figure 4.14. [Rh(HDPA)2chrysi]3+ induced necrosis is concentration dependent. 
HCT116N and HCT116O cells were treated with 0–30 µM [Rh(HDPA)2chrysi]3+ for 72 
hours.  Cells were harvested, resuspended in PBS, and stained with PI (dead cell 
permeable) and YO-PRO1 (apoptotic cell permeable).  The cells were gated by regions in 
the fluorescence plane and classified as live, apoptotic, necrotic, or dead.  Rhodium 
treatment causes a sharp decrease in the live population of the HCT116O cell line with a 
corresponding increase in the necrotic and dead cell populations.  Minimal effect is seen 
in the HCT116N cell line.   
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Figure 4.15. [Rh(HDPA)2chrysi]3+ induced necrosis increases over 24 to 72 hours. 
HCT116N and HCT116O cells were treated with 20 µM or 25 µM [Rh(HDPA)2chrysi]3+ 
for 24–72 hours.  Cells were harvested, resuspended in PBS, and stained with PI (dead 
cell permeable) and YO-PRO1 (apoptotic cell permeable).  The cells were gated by 
regions in the fluorescence plane and classified as live, apoptotic, necrotic, or dead.  
Rhodium treatment causes a sharp decrease in the live population of the HCT116O cell 
line with a corresponding increase in the necrotic and dead cell populations.  Minimal 
effect is seen in the HCT116N cell line. 
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Finally, figure 4.16 shows histograms of live, apoptotic, necrotic, and dead cells for the 
HCT116N and HCT116O cell lines treated with a combination of rhodium and the 
dihydrofolate reductase (DHFR) inhibitor methotrexate. Rhodium treatment was either 20 
or 25 µM [Rh(HDPA)2chrysi]3+ for 72 hours, and methotrexate treatment was 500 nM for 
72 hours.  As before, rhodium treatment alone induces necrosis preferentially in the 
MMR-deficient HCT116O cell line; there is no significant change in the percentage of 
cells in the apoptotic region in either cell line.  The effect is more pronounced in the 
MMR-deficient HCT116O cell line, which drops from 79 ± 3.8 %  to 37 ± 5.3 % after 
treatment with 20 µM [Rh(HDPA)2chrysi]3+ and to 27 ± 8.9 % after treatment with 20 
µM [Rh(HDPA)2chrysi]3+ and 500 nM methotrexate, versus the MMR-proficient 
HCT116N cell line, which shows a minimal decrease in live cells from 62 ± 0.6 % to 54 
± 5.1 % after treatment with 20 µM [Rh(HDPA)2chrysi]3+ and to 53 ± 1.0 % after 
treatment with 20 µM [Rh(HDPA)2chrysi]3+ and 500 nM methotrexate. 
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Figure 4.16. [Rh(HDPA)2chrysi]3+ induces necrosis in combination with 
methotrexate (MTX). HCT116N and HCT116O cells were treated with 20 µM 
[Rh(HDPA)2chrysi]3+ for 24–72 hours.  Cells were harvested, resuspended in PBS, and 
stained with PI (dead cell permeable) and YO-PRO1 (apoptotic cell permeable).  The 
cells were gated by regions in the fluorescence plane and classified as live, apoptotic, 
necrotic, or dead.  Rhodium treatment causes a sharp decrease in the live population of 
the HCT116O cell line with a corresponding increase in the necrotic and dead cell 
populations.  Minimal effect is seen in the HCT116N cell line.   
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4.3.5 Caspase Inhibitor MTT 
As a complement to the dye exclusion flow cytometry assay, the MTT cytotoxicity assay 
was repeated in the absence and presence of the pan-caspase inhibitor Z-VAD-FMK 
(figure 4.17).12 This inhibitor works by irreversibly binding to the active site of caspases.  
As before, the HCT116N and HCT116O cell lines were treated with 0–30 µM of the 
[Rh(HDPA)2chrysi]3+ complex for 24–72 hours.  In addition, each treatment was also 
combined with the inhibitor at a final concentration of 20 µM (figure 4.18) or 40 µM 
(figure 4.19).  As before, the rhodium complex exhibited selective toxicity in the repair-
deficient HCT116O cell line, with cell viability dropping to 9.7 ± 4.4 % after treatment 
with 30 µM metal complex for 72 hours, versus 63 ± 5.7 % viability in the repair-
proficient HCT116N cell line.  Addition of the caspase inhibitor at 20 µM offered no 
protection from rhodium to the HCT116N cell line (63 ± 5.7 % without inhibitor, 52 ± 
9.8 % with inhibitor) or to the HCT116O cell line (9.7 ± 4.4 % without inhibitor, 9.8 ± 
7.8 % with inhibitor).  At a final concentration of 40 µM, the caspase inhibitor provided 
some protection from rhodium to the HCT116O cell line (16 ± 10 % without inhibitor, 28 
± 3.7 % with inhibitor), but this difference was small in relation to the differential 
between the HCT116N and HCT116O cell lines and roughly within error. 
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Figure 4.17. Z-VAD-fmk caspase inhibitor.   
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Figure 4.18. 20 µM Caspase inhibition assay. HCT116N and HCT116O cells were 
plated in 96-well format at densities of 5 x 104 cells/well and treated with 0–30 µM of 
[Rh(HDPA)2chrysi]3+ with or without 20 µM of the pan-caspase inhibitor Z-VAD-FMK.  
After 24–72 hours, the cells were labeled with MTT for 4 hours.  The resulting formazan 
crystals were dissolved by addition of 10% SDS acidified with 10 mM HCl, and 
absorbance was measured at 570 nm.  The caspase inhibitor confers no protection from 
rhodium-induced toxicity in either cell line.  
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Figure 4.19. 40 µM Caspase inhibition assay. HCT116N and HCT116O cells were 
plated in 96-well format at densities of 5 x 104 cells/well and treated with 0–30 µM of 
[Rh(HDPA)2chrysi]3+ with or without 40 µM of the pan-caspase inhibitor Z-VAD-FMK.  
After 24–72 hours, the cells were labeled with MTT for 4 hours.  The resulting formazan 
crystals were dissolved by addition of 10% SDS acidified with 10 mM HCl, and 
absorbance was measured at 570 nm.  The caspase inhibitor confers no protection from 
rhodium-induced toxicity in either cell line.  
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4.3.6 PARP Inhibitor MTT 
The MTT cytotoxicity assay was also repeated in the conjunction with the PARP 
inhibitor DPQ (figure 4.20). As before, the HCT116N and HCT116O cell lines were 
treated with 0 or 20 µM of the [Rh(HDPA)2chrysi]3+ complex for 72 hours, with 0–50 
µM of DPQ.  The rhodium complex alone exhibited selective toxicity in the repair-
deficient HCT116O cell line, with cell viability dropping to 9.7 ± 4.4 % versus 63 ± 5.7 
% viability in the repair-proficient HCT116N cell line.  Addition of the caspase inhibitor 
at 50 µM offered protection from rhodium to both cell lines (HCT116N: 39 ± 3.6 % 
without inhibitor, 47 ± 2.1% with inhibitor, HCT116O: 14 ± 1.7 % without inhibitor, 41 
± 2.0 % with inhibitor).  Importantly, this inhibition significantly decreased the 
differential in toxicity (25 ± 4.0 % without inhibitor, 6.4 ± 2.9 % with inhibitor) between 
the cell lines, suggesting that PARP is involved in the MMR-dependent response to 
[Rh(HDPA)2chrysi]3+. 
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Figure 4.20. PARP inhibition assay. HCT116N and HCT116O cells were plated in 96-
well format at densities of 5 x 104 cells/well and treated with 0 or 20 µM of 
[Rh(HDPA)2chrysi]3+ with or without 25 or 50 µM of the PARP inhibitor DPQ.  After 72 
hours, the cells were labeled with MTT for 4 hours.  The resulting formazan crystals were 
dissolved by addition of 10% SDS acidified with 10 mM HCl, and absorbance was 
measured at 570 nm.  The PARP inhibitor confers protection from rhodium-induced 
toxicity in both cell lines, reducing the differential activity significantly.  
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4.4. Discussion 
ICP-MS affords a relative comparison of the cellular accumulation of a series of rhodium 
metalloinsertors after treatments similar to those applied in ELISA assays for activity.  
The highest levels of cellular accumulation are clearly seen for the complex bearing the 
HDPA ligand, which was expected in light of the previous observation that 
[Rh(HDPA)2chrysi]3+ exhibits increased activity against the HCT116 cell lines at shorter 
incubation times than other rhodium metalloinsertors.  Significant activity is seen with 
[Rh(HDPA)2chrysi]3+ in as little as 12 hours, while [Rh(bpy)2chrysi]3+ and 
[Rh(NH3)4chrysi]3+ display no activity at this incubation time.  There are several possible 
explanations for the increased rate of uptake. The central amine may make the HDPA 
ligands more flexible than bpy ligands, allowing the complex to deform more easily and 
increasing its ability to diffuse through the plasma membrane.  Alternatively, the 
hydrogen bonding capability may facilitate active uptake by fostering interaction with 
some unknown transport protein. 
Rhodium metalloinsertors have shown differential anti-proliferative activity in an 
ELISA assay for DNA synthesis.  This assay directly reports on the amount of BrdU label 
incorporated during DNA replication, and as such, does not distinguish between cells that 
are viable but not replicating, e.g., G0 cells that have exited the cell cycle, and cells that 
are inviable, or dead.  Therefore, this assay can be used to determine inhibitory, but not 
cytotoxic activity.  In contrast, the MTT assay reports directly on cell viability as 
measured by metabolic activity, with the action of mitochondrial reductases catalyzing 
the cleavage of the labeling agent MTT.  Here cells that are viable still produce signal, 
i.e., formazan absorbance, whether or not they are actively dividing.  Thus, this assay can 
distinguish between senescence and true cell death, and the effects observed in response 
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to rhodium treatment are truly cytotoxic.  Importantly, the concentration ranges and 
incubation times of the treatments applied in the MTT assays for [Rh(HDPA)2chrysi]3+ 
and the closely related complex [Rh(MeDPA)2chrysi]3+ (0–50 µM, 24–72 hours) are 
similar, if not identical, to those that inhibit DNA synthesis as seen by ELISA (0–25 µM, 
24–72 hours). 
Accordingly, the result that [Rh(HDPA)2chrysi]3+ and [Rh(MeDPA)2chrysi]3+ 
trigger cell death selectively in the MMR-deficient HCT116O cell line versus the MMR-
proficient HCT116N cell line as measured by MTT assay represents a significant advance 
in the development of these complexes as anti-cancer agents; clearly, these agents are 
more potent that previously understood.  Although [Rh(bpy)2chrysi]3+ does not appear to 
be selectively toxic at these concentrations, it is likely that this is due to differences in the 
kinetics of cellular uptake, rather than fundamental differences in its mode of action as 
compared to [Rh(HDPA)2chrysi]3+, since both bind DNA mismatches with equal affinity 
(Chapter 3).  For either activity assay, the complex must first accumulate within the cell, 
and then cellular response must be triggered.  While [Rh(HDPA)2chrysi]3+ displays 
activity in ELISA after 12 hour incubations, [Rh(bpy)2chrysi]3+ requires 48 hours or more 
to show significant differential activity.  In light of the higher levels of rhodium 
accumulation seen by ICP-MS after treatment with the HDPA complex versus the bpy 
complex, it seems likely that accumulation of the bpy complex is delayed by ~36 hours 
relative to the HDPA complex.  Cellular responses that occur quickly after accumulation, 
such as the inhibition of DNA synthesis, can still be observed within the 72 hour 
timeframe of the ELISA assay, and both complexes display activity. However, a lag time 
will exist between the inhibition of DNA synthesis and the onset of cell death, and when 
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combined with the slow uptake of [Rh(bpy)2chrysi]3+, (t > 48 hours), cell death is delayed 
accordingly and cannot be observed within the timeframe of the MTT assay (also 72 
hours). 
The fact that the [Rh(MeDPA)2chrysi]3+ complex displays differential toxicity 
against the HCT116O cell lines comparable to that of the [Rh(HDPA)2chrysi]3+ complex 
suggests that it shares the accelerated uptake of the HDPA complex.  This was certainly 
expected, as the complexes are almost identical, but does address the question of uptake 
mechanism, and clearly refutes the hypothesis that accelerated uptake requires a 
hydrogen bonding interaction with the bridging secondary amine of the HDPA ligand.  
More importantly, this suggests that selective toxicity as a function of MMR-competency 
is a general property of rhodium metalloinsertors with dipyridylamine ancillary ligands, 
and establishes these ligands as the basis for the development of the next generation of 
complexes. 
Flow cytometry analysis reveals that cell death is preceded by disruption of the 
cell cycle.  Treatment with 20 µM [Rh(HDPA)2chrysi]3+ for 24 hours leads to a marked 
depletion of the S-phase population with a concomitant increase in the G1 population.  
These data suggest that the G1/S-phase DNA damage checkpoint may be activated in 
response to rhodium treatment, and call for biochemical assays to probe for 
phosphorylation of checkpoint kinases such as Chk1 and Chk2 that arrest the cell cycle in 
response to DNA damage.  In the case of the HCT116O line, the G2/M-phase population 
also increases in response to rhodium treatment.  This could represent a secondary 
checkpoint activation occuring at the G2/M-phase transition, and might signal a “two-
alarm fire” that accompanies the enhanced activity against this cell line.  Again, 
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additional biochemical assays are needed to probe the regulatory network controlling this 
checkpoint. 
The two main modes of cell death are apoptosis and necrosis.  The biochemical 
events associated with apoptosis have been extensively studied since Kerr and Wylie’s 
seminal paper13 in 1972.  An extensive network of regulatory proteins controls the 
initiation of this process in response to both internal and external signals.14 Upon 
activation, the cascade of initiator and effector caspases cleaves a variety of substrates to 
bring about the morphological changes associated with this mode of cell death, including 
nuclear condensation and fragmentation, plasma membrane blebbing, decomposition of 
the cell into apoptotic bodies, and ultimately, the engulfment of these bodies by 
neighboring cells through phagocytosis.15 Importantly, apoptotic cells retain their 
membrane integrity until the very last stages of this process, preventing release of 
cytokines and thus avoiding inflammation.  By comparison, both the causes and the 
progression of necrosis are much less defined at the molecular level, and this mode of cell 
death is most frequently characterized by morphological criteria.15-17 Perhaps the most 
reliable marker of necrosis then, is the early rupture of the plasma membrane, in direct 
contrast to apoptosis.  These differences in membrane integrity enable the facile 
characterization of cell death by flow cytometry assay.  The admission of the dead cell 
stain propidium iodide by the HCT116 cell lines upon rhodium treatment reveals that cell 
death proceeds through a necrotic, rather than apoptotic, pathway.  This conclusion is 
supported by the observation that the caspase inhibitor Z-VAD-fmk is unable to block 
rhodium-induced toxicity in the MTT assay, indicating that death occurs in a caspase-
independent fashion. 
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It is interesting to consider that rhodium metalloinsertors selectively induce 
necrosis in MMR-deficient cells.  Traditionally, necrotic cell death has been considered 
to be “accidental,” occurring mainly in response to non-physiological insults.18,19 More 
recently however, the notion that necrosis may in fact be an ancestral mode of 
programmed cell death has gained attention in the literature and community of cell death 
research.15,16 Hitomi et al. screened an siRNA library covering the mouse genome and 
identified 432 gene knockdowns that blocked the induction of necrosis.21 Chan et al. 
found anti-necrotic proteins encoded in the genomes of several viruses.22 While these 
studies present some of the most compelling evidence for the notion that necrosis is in 
fact a regulated process, several other groups are also working to provide a molecular 
definition for the process as has been done for apoptosis.19,20  
Thompson and co-workers have reported that the DNA repair protein poly ADP-
ribose polymerase-1 (PARP-1) mediates the induction of necrosis in response to DNA 
damage by the alkylator MNNG.23 Upon activation at sites of DNA damage, PARP-1 
covalently modifies itself with long chains of ADP-ribose polymers in order to recruit 
downstream components of the repair machinery.24 As a result, PARP-1 along with 
PARP-2 has attracted much attention as a therapeutic target recently, and several specific 
and potent inhibitors of the enzyme are currently in clinical trials.25 Here, treatment with 
the PARP inhibitor DPQ rescues cells from rhodium-induced toxicity.  This suggests that 
PARP is involved in the induction of necrosis by rhodium metalloinsertors, and may 
represent the first molecular insight into the events underlying rhodium toxicity.  
Although the role of PARP in regulating necrosis is still emerging, confirmation that 
these rhodium complexes activate PARP as a component of a broader DNA damage 
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response would support the notion that rhodium metalloinsertors target mismatches in 
genomic DNA. 
As necrosis triggers a proinflammatory response by releasing cytokines, selective 
induction of necrosis in cancerous tissues may be a way to activate the immune system 
against cancer cells and ultimately improve efficacy of a therapeutic agent.26 One 
accepted trigger of necrosis is bioenergetic catastrophe, i.e., severe ATP depletion.18,19 
Rhodium metalloinsertors might trigger such a catastrophe by targeting mitochondrial 
DNA. Previously, it was thought that damaged mitochondrial genomes simply would be 
degraded and replaced by the replication of undamaged DNA.27 However, emerging 
research has uncovered DNA repair processes in mitochondria, including mismatch 
repair capability.27,28 As lipophilic cations, rhodium metalloinsertors likely accumulate in 
mitochondria,6-11 as we have seen with analogous ruthenium complexes in our 
laboratory.29 If mitochondrial DNA mismatches are in fact a target for rhodium 
metalloinsertors, then the resultant disruption of mitochondrial function would lead to 
energy depletion and necrosis.  Future mechanistic work must explore the biochemical 
consequences of mismatch binding in nuclear DNA versus mitochondrial DNA.  It 
should be noted that these mechanisms are not mutually exclusive; as such, both might 
contribute to the biological response to rhodium metalloinsertors. 
4.5. Conclusions 
These studies support the notion that rhodium metalloinsertors bearing HDPA ligands 
benefit from increased cellular accumulation, and thus provide an explanation for the 
observation that [Rh(HDPA)2chrysi]3+ exceeds the activity predicted by its binding 
affinity for DNA mismatches.   
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Figure 4.21. Model of the cellular response to rhodium metalloinsertors. 
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This increased uptake allows us to observe additional cellular responses to these agents, 
and, as a whole, a picture of the biological response to rhodium metalloinsertors, 
exemplified by [Rh(HDPA)2chrysi]3+ in particular, is beginning to emerge (figure 4.21).  
Over the course of the first 12 hours, the rhodium complex accumulates in cells, binding 
to either mitochondrial or genomic DNA mismatches.  Within 24 hours, DNA synthesis 
is inhibited, and cells accumulate in G1 phase.  Over the next 24–48 hours, the DNA 
damage response is likely activated, and ultimately leads to cell death by a caspase-
independent, necrotic mechanism.  These biological effects are more pronounced at each 
stage of the response in the MMR-deficient HCT116O cell line relative to the MMR-
proficient HCT116N cell line, strongly suggesting that DNA mismatches are in fact the 
cellular target of rhodium metalloinsertors.  Furthermore, these cellular responses are 
consistent with the idea that repair proteins are activated in response to DNA mismatch 
binding. 
The structural analogue [Rh(MeDPA)2chrysi]3+ is also shown to be toxic, 
suggesting that dipyridylamine ancillary ligands in general can serve to accelerate uptake, 
and form the foundation for the next generation of complex development.  This new class 
of agents is significantly more potent than previously understood, and the work begun 
here on understanding their mechanism of action advances their development as novel 
anti-cancer agents. 
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Conclusion 
 
Modern drug development harnesses the power of screening-based approaches to identify 
many natural products and lead compounds with great promise as therapeutic agents.  Yet 
these efforts come at great cost, and only a small fraction of compounds tested are 
ultimately successful.  This work argues that the rational design of new agents can play 
an important role in contributing to the development pipeline, especially when the design 
effort is founded on thoughtful chemical insight and meaningful experimental validation. 
Rhodium metalloinsertors are well-defined chemical agents whose ability to 
target mismatches has been extensively characterized in vitro.  This thesis was the first 
step in exploring their functionality in a biological system, with all its inherent 
complexity.  It should be noted that the activity of rhodium metalloinsertors against 
human cancer cell lines was, like so many other scientific discoveries, somewhat 
fortuitous.  The in vitro development of these complexes suggested that as non-covalent 
DNA binders, they might require photoactivation to exert a biological effect.  The strong 
and selective activity against MMR-deficient cells in the absence of irradiation was first 
observed then as the unexpected result of a necessary control. 
Our work has sought to capitalize on this good fortune and to realize all the 
promise of these unique agents.  The characterization of the cellular responses to rhodium 
metalloinsertors not only demonstrates their potential, but also provides critical insights 
that will direct future explorations at the molecular level. 
While the discoveries we have made are exciting in themselves, the story does not 
end here by any means.  The ultimate goal of this work is not simply success in an 
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academic setting.  It is our hope and deepest desire that as ongoing research continues to 
elucidate further the basis of activity and to inform the design of new complexes, the 
development of these agents will graduate from the bench to the clinic, and someday 
provide a class of targeted and useful weapons in the fight against cancer. 
